

B160

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07K 14/00</b>		<b>A2</b>	(11) International Publication Number: <b>WO 99/58558</b> (43) International Publication Date: 18 November 1999 (18.11.99)
(21) International Application Number: PCT/US99/10567 (22) International Filing Date: 13 May 1999 (13.05.99) (30) Priority Data: 60/085,343      13 May 1998 (13.05.98)      US 60/098,010      26 August 1998 (26.08.98)      US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US      60/085,343 (CIP) Filed on      13 May 1998 (13.05.98) US      60/098,010 (CIP) Filed on      26 August 1998 (26.08.98) (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US).		YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). YANG, Junming [CN/US]; 7136 Clarendon Street, San Jose, CA 95129 (US). (74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	
(54) Title: CELL SIGNALING PROTEINS			
(57) Abstract			
The invention provides human cell signaling proteins (CSIGP) and polynucleotides which identify and encode CSIGP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or prevention disorders associated with expression of CSIGP.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## CELL SIGNALING PROTEINS

### TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of cell signaling proteins  
5 and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative  
and inflammatory disorders.

### BACKGROUND OF THE INVENTION

10 Signal transduction is the process of biochemical events by which cells respond to  
extracellular signals. Extracellular signals are transduced through a biochemical cascade that  
begins with the binding of a signal molecule such as a hormone, neurotransmitter, or growth  
factor, to a cell membrane receptor and ends with the activation of an intracellular target molecule.  
The process of signal transduction regulates a wide variety of cell functions including cell  
15 proliferation, differentiation, and gene transcription.

Signal transduction is the general process by which cells respond to extracellular signals  
(hormones, neurotransmitters, growth and differentiation factors, etc.) through a cascade of  
biochemical reactions that begins with the binding of the signaling molecule to a cell membrane  
receptor and ends with the activation of an intracellular target molecule. Intermediate steps in this  
20 process involve the activation of various cytoplasmic proteins by phosphorylation via protein  
kinases and the eventual translocation of some of these activated proteins to the cell nucleus where  
the transcription of specific genes is triggered. Thus, the signal transduction process regulates all  
types of cell functions including cell proliferation, differentiation, and gene transcription.

Protein kinases play a key role in the signal transduction process by phosphorylating and  
25 activating various proteins involved in signaling pathways. The high energy phosphate which  
drives this activation is generally transferred from adenosine triphosphate molecules (ATP) to a  
particular protein by protein kinases and removed from that protein by protein phosphatases.  
Phosphorylation occurs in response to extracellular signals, cell cycle checkpoints, and  
environmental or nutritional stresses. Protein kinases are roughly divided into two groups; those  
30 that phosphorylate tyrosine residues (protein tyrosine kinases, PTK) and those that phosphorylate  
serine or threonine residues (serine/threonine kinases, STK). A few protein kinases have dual  
specificity for serine/threonine and tyrosine residues. Almost all kinases contain a similar 250-300  
amino acid catalytic domain containing specific residues and sequence motifs characteristic of the  
kinase family. (Hardie, G. and Hanks, S. (1995) The Protein Kinase Facts Books, Vol I:7-20

Academic Press, San Diego, CA.)

STKs include the second messenger dependent protein kinases such as the cyclic-AMP dependent protein kinases (PKA), which are involved in mediating hormone-induced cellular responses; calcium-calmodulin (CaM) dependent protein kinases, which are involved in regulation of smooth muscle contraction, glycogen breakdown, and neurotransmission; and the mitogen-activated protein kinases (MAP) which mediate signal transduction from the cell surface to the nucleus via phosphorylation cascades. Altered PKA expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease. (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, New York, NY, pp. 416-431, 1887.)

PTKs are divided into transmembrane, receptor PTKs and nontransmembrane, non-receptor PTKs. Transmembrane protein-tyrosine kinases are receptors for most growth factors which include epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor. Non-receptor PTKs lack transmembrane regions and, instead, form complexes with the intracellular regions of cell surface receptors. Receptors that function through non-receptor PTKs include those for cytokines, hormones (growth hormone and prolactin) and antigen-specific receptors on T and B lymphocytes.

Many of these PTKs were first identified as the products of mutant oncogenes in cancer cells where their activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs, and it is well known that cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity. (Charbonneau H and Tonks NK (1992) *Annu Rev Cell Biol* 8:463-493.)

Protein phosphatases regulate the effects of protein kinases by removing phosphate groups from molecules previously activated by kinases. The two principle categories of protein phosphatases are the protein phosphatases (PPs) and the protein tyrosine phosphatases (PTPs). PPs dephosphorylate phosphoserine/threonine residues and are important regulators of many cAMP-mediated hormone responses in cells. (Cohen, P. (1989) *Annu. Rev. Biochem.* 58:453-508.) PTPs reverse the effects of protein tyrosine kinases and play a significant role in cell cycle and cell signaling processes. (Charbonneau and Tonks, *supra*.) In the process of cell division, for example, a specific PTP (M-phase inducer phosphatase) plays a key role in the induction of mitosis by dephosphorylating and activating a specific PTK (CDC2) leading to cell division. (Sadu, K.. et al. (1990) *Proc. Natl. Acad. Sci.* 87:5139-5143.)

Guanine nucleotide binding proteins (GTP-binding proteins) are critical mediators of the signal transduction pathway. Extracellular ligands such as hormones, growth factors,



neuromodulators, or other signaling molecules bind to transmembrane receptors, and the signal is propagated to effector molecules by intracellular signal transducing proteins. Many of these signal transduction proteins are GTP-binding proteins which regulate intracellular signaling pathways. GTP-binding proteins participate in a wide range of other regulatory functions including

5 metabolism, growth, differentiation, cytoskeletal organization, and intracellular vesicle transport and secretion. Exchange of bound GDP for GTP followed by hydrolysis of GTP to GDP provides the energy that enables GTP-binding proteins to alter their conformation and interact with other cellular components. Two structurally distinct classes of GTP-binding proteins are recognized: heterotrimeric GTP-binding proteins, consisting of three different subunits, and monomeric, low

10 molecular weight (LMW), GTP-binding proteins consisting of a single polypeptide chain.

G protein coupled receptors (GPCR) are a superfamily of integral membrane proteins which transduce extracellular signals. GPCRs include receptors for biogenic amines, mediators of inflammation, peptide hormones, and sensory signal mediators. A GPCR becomes activated when the receptor binds to its extracellular ligand. The beta subunit of the GPCR, which consists of an

15 amino-terminal helical segment followed by seven WD, or  $\beta$  transducin repeats, transduces signals across the plasma membrane. Conformational changes in the GPCR, resulting from the ligand-receptor interaction, promote the binding of GTP to the GPCR intracellular domains. GTP binding to the GPCR leads to the interaction of the GPCR alpha subunit with adenylate cyclase or other second messenger molecule generators. This interaction regulates the activity of second

20 messenger molecules such as cAMP, cGMP, or eicosinoids which, in turn, regulate phosphorylation and activation of other intracellular proteins. The GPCR changes conformation upon hydrolysis of the bound GTP by GTPases, dissociates from the second messenger molecule generator, and returns to its initial pre-ligand binding conformation.

G beta proteins, also known as  $\beta$  transducins, contain seven tandem repeats of the WD-repeat sequence motif, a motif found in many proteins with regulatory functions. WD-repeat

25 proteins contain from four to eight copies of a loosely conserved repeat of approximately 40 amino acids which participates in protein-protein interactions. Mutations and variant expression of  $\beta$  transducin proteins are linked with various disorders. Mutations in LIS1, a subunit of the human platelet activating factor acetylhydrolase, cause Miller-Dieker lissencephaly. RACK1

30 binds activated protein kinase C, and RbAp48 binds retinoblastoma protein. CstF is required for polyadenylation of mammalian pre-mRNA in vitro and associates with subunits of cleavage-stimulating factor. CD4, an integral membrane glycoprotein which functions as an HIV co-receptor for infection of human host cells is degraded by HIV-encoded Vpu in the endoplasmic reticulum. WD repeats of human beta TrCP molecule mediate the formation of the CD4- Vpu,

35 inducing CD4 proteolysis (Neer, E.J. et al. (1994) Nature 371:297-300 and Margottin, F. et al.

(1998) Mol. Cell. 1:565-574).

Irregularities in the GPCR signaling cascade may result in abnormal activation of leukocytes and lymphocytes, leading to the tissue damage and destruction seen in many inflammatory and autoimmune diseases such as rheumatoid arthritis, biliary cirrhosis, hemolytic anemia, lupus erythematosus, and thyroiditis. Abnormal cell proliferation, including cyclic AMP stimulation of brain, thyroid, adrenal, and gonadal tissue proliferation is regulated by G proteins. Mutations in G<sub>α</sub> subunits have been found in growth-hormone-secreting pituitary somatotroph tumors, hyperfunctioning thyroid adenomas, and ovarian and adrenal neoplasms (Meij, J.T.A. (1996) Mol. Cell. Biochem. 157:31-38; Aussel, C. et al. (1988) J. Immunol. 140:215-220).

10 LMW GTP-binding proteins regulate cell growth, cell cycle control, protein secretion, and intracellular vesicle interaction. They consist of single polypeptides which, like the alpha subunit of the heterotrimeric GTP-binding proteins, are able to bind to and hydrolyze GTP, thus cycling between an inactive and an active state. LMW GTP-binding proteins respond to extracellular signals from receptors and activating proteins by transducing mitogenic signals involved in  
15 various cell functions. The binding and hydrolysis of GTP regulates the response of LMW GTP-binding proteins and acts as an energy source during this process (Bokoch, G. M. and Der, C. J. (1993) FASEB J. 7:750-759).

At least sixty members of the LMW GTP-binding protein superfamily have been identified and are currently grouped into the four subfamilies of ras, rho, arf, sar1, ran, and rab.  
20 Activated ras genes were initially found in human cancers and subsequent studies confirmed that ras function is critical in determining whether cells continue to grow or become differentiated. Other members of the LMW G-protein superfamily have roles in signal transduction that vary with the function of the activated genes and the locations of the GTP-binding proteins that initiate the activity. Rho GTP-binding proteins control signal transduction pathways that link growth factor  
25 receptors to actin polymerization, which is necessary for normal cellular growth and division. The rab, arf, and sar1 families of proteins control the translocation of vesicles to and from membranes for protein localization, protein processing, and secretion. Ran GTP-binding proteins are located in the nucleus of cells and have a key role in nuclear protein import, the control of DNA synthesis, and cell-cycle progression (Hall, A. (1990) Science 249:635-640; Barbacid, M. (1987) Ann. Rev  
30 Biochem. 56:779-827; and Sasaki, T. and Takai, Y. (1998) Biochem. Biophys. Res. Commun. 245:641-645).

LMW GTP-binding proteins are GTPases which cycle between a GTP-bound active form and a GDP-bound inactive form. This cycle is regulated by proteins that affect GDP dissociation, GTP association, or the rate of GTP hydrolysis. Proteins affecting GDP association are

represented by guanine nucleotide dissociation inhibitors and guanine nucleotide exchange factors (GEP). The best characterized is the mammalian homologue of the *Drosophila* Son-of-Sevenless protein. Proteins affecting GTP hydrolysis are exemplified by GTPase-activating proteins (GAP). Both GEP and GAP activity may be controlled in response to extracellular stimuli and modulated  
5 by accessory proteins such as RalBP1 and POB1. The GDP-bound form is converted to the GTP-bound form through a GDP/GTP exchange reaction facilitated by guanine nucleotide-releasing factors. The GTP-bound form is converted to the GDP-bound form by intrinsic GTPase activity, and the conversion is accelerated by GAP (Ikeda, M. et al. (1998) *J. Biol. Chem.* 273:814-821; Quilliam, L. A. (1995) *Bioessays* 17:395-404.). Mutant Ras-family  
10 proteins, which bind but can not hydrolyze GTP, are permanently activated, and cause cell proliferation or cancer, as do GEP that activate LMW GTP-binding proteins (Drivas, G. T. et al. (1990) *Mol. Cell. Biol.* 10:1793-1798; and Whitehead, I. P. et al. (1998) *Mol Cell Biol.* 18:4689-4697.)

The discovery of new cell signaling proteins and the polynucleotides encoding them  
15 satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative and inflammatory disorders.

#### SUMMARY OF THE INVENTION

20 The invention features substantially purified polypeptides, cell signaling proteins, referred to collectively as "CSIGP" and individually as CSIGP-1 through CSIGP-13. In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-13, and fragments thereof.

The invention further provides a substantially purified variant having at least 90% amino  
25 acid identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-13, and fragments thereof. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-13, and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 70% polynucleotide sequence identity  
30 to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-13, and fragments thereof.

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-13, and fragments  
35 thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino

acid sequence selected from the group consisting of SEQ ID NO:1-13, and fragments thereof.

The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:14-26, and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 70% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:14-26 and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:14-26 and fragments thereof.

10 The invention also provides a method for detecting a polynucleotide in a sample containing nucleic acids, the method comprising the steps of (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-13, and fragments thereof. In another aspect, the expression vector is contained within a host cell.

20 The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide under conditions suitable for the expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-13, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide selected from the group consisting of SEQ ID NO:1-13, and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

30 The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of CSIGP, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-13, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of CSIGP, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-13, and fragments thereof, in  
5 conjunction with a suitable pharmaceutical carrier.

#### BRIEF DESCRIPTION OF THE TABLES

Table 1 shows nucleotide and polypeptide sequence identification numbers (SEQ ID NO), clone identification numbers (clone ID), cDNA libraries, and cDNA fragments used to assemble  
10 full-length sequences encoding CSIGP.

Table 2 shows features of each polypeptide sequence including potential motifs, homologous sequences, and methods and algorithms used for identification of CSIGP.

Table 3 shows the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis, diseases, disorders or conditions associated with these tissues,  
15 and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which Incyte cDNA clones encoding CSIGP were isolated.

Table 5 shows the programs, their descriptions, references, and threshold parameters used to analyze CSIGP.

20

#### DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the  
25 purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an  
30 antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described  
35 herein can be used to practice or test the present invention, the preferred machines, materials and

methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of  
5 prior invention.

#### DEFINITIONS

"CSIGP" refers to the amino acid sequences of substantially purified CSIGP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and preferably the human species, from any source, whether natural, synthetic,  
10 semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which, when bound to CSIGP, increases or prolongs the duration of the effect of CSIGP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of CSIGP.

An "allelic variant" is an alternative form of the gene encoding CSIGP. Allelic variants  
15 may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination  
20 with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding CSIGP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polynucleotide the same as CSIGP or a polypeptide with at least one functional characteristic of CSIGP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular  
25 oligonucleotide probe of the polynucleotide encoding CSIGP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding CSIGP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent CSIGP. Deliberate amino acid substitutions may be made  
30 on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of CSIGP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine,  
35 and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and

phenylalanine and tyrosine.

The terms "amino acid" or "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments," "immunogenic fragments," or "antigenic fragments" refer to fragments of CSIGP which are preferably at least 5 to about 15 amino acids in length, most preferably at least 14 amino acids, and which retain some biological activity or immunological activity of CSIGP. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which, when bound to CSIGP, decreases the amount or the duration of the effect of the biological or immunological activity of CSIGP. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of CSIGP.

The term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind CSIGP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form

duplexes and to block either transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

The term "biologically active," refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic CSIGP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" or "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" or a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding CSIGP or fragments of CSIGP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW Fragment Assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

The term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding CSIGP, by northern analysis is indicative of the presence of nucleic acids encoding CSIGP in a sample, and thereby correlates with expression of the transcript from the polynucleotide encoding CSIGP.



A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

10 The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

25 The phrases "percent identity" or "% identity" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, e.g., by using the MEGALIGN program (DNASTAR, Madison WI). The MEGALIGN program can create alignments between two or more sequences according to different methods, e.g., the clustal method. (See, e.g., Higgins, D.G. and P.M. Sharp 30 (1988) Gene 73:237-244.) The clustal algorithm groups sequences into clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, e.g., sequence A and sequence B, is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and sequence B, times one hundred. Gaps of low or of no similarity between the two amino acid 35

sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known in the art, e.g., the Jotun Hein method. (See, e.g., Hein, J. (1990) *Methods Enzymol.* 183:626-645.) Identity between sequences can also be determined by other methods known in the art, e.g., by varying  
5 hybridization conditions.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

The term "humanized antibody" refers to antibody molecules in which the amino acid  
10 sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

The term "hybridization complex" refers to a complex formed between two nucleic acid  
15 sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g.,  $C_0t$  or  $R_0t$  analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

20 The words "insertion" or "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by  
25 expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

The terms "element" or "array element" in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

30 The term "modulate" refers to a change in the activity of CSIGP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of CSIGP.

The phrases "nucleic acid" or "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or  
35 RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may

represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material. In this context, "fragments" refers to those nucleic acid sequences which, when translated, would produce polypeptides retaining some functional characteristic, e.g., antigenicity, or structural domain characteristic, e.g., ATP-binding site, of the full-length  
5 polypeptide.

The terms "operably associated" or "operably linked" refer to functionally related nucleic acid sequences. A promoter is operably associated or operably linked with a coding sequence if the promoter controls the translation of the encoded polypeptide. While operably associated or operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain  
10 genetic elements, e.g., repressor genes, are not contiguously linked to the sequence encoding the polypeptide but still bind to operator sequences that control expression of the polypeptide.

The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in a hybridization assay or  
15 microarray. "Oligonucleotide" is substantially equivalent to the terms "amplimer," "primer," "oligomer," and "probe," as these terms are commonly defined in the art.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition.  
20 PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding CSIGP, or fragments thereof, or CSIGP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic  
25 DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" or "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the  
30 presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "stringent conditions" refers to conditions which permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be defined by salt  
35 concentration, the concentration of organic solvent, e.g., formamide, temperature, and other

conditions well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of CSIGP polypeptides refers to an amino acid sequence that is altered by one or more amino acid residues. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to CSIGP. This definition may also include, for example, "allelic" (as defined above), "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or

lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A

- 5 polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

## 10 THE INVENTION

The invention is based on the discovery of new human cell signaling proteins (CSIGP), the polynucleotides encoding CSIGP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative and inflammatory disorders.

- Table 1 lists the Incyte Clones used to derive full length nucleotide sequences encoding CSIGP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NO) of the amino acid and nucleic acid sequences, respectively. Column 3 shows the Clone ID of the Incyte Clone in which nucleic acids encoding each CSIGP were first identified, and column 4, the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones, their corresponding cDNA libraries, and shotgun sequences useful as fragments in hybridization
- 15 CSIGP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NO) of the amino acid and nucleic acid sequences, respectively. Column 3 shows the Clone ID of the Incyte Clone in which nucleic acids encoding each CSIGP were first identified, and column 4, the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones, their corresponding cDNA libraries, and shotgun sequences useful as fragments in hybridization
- 20 technologies, and which are part of the consensus nucleotide sequence of each CSIGP.

- The columns of Table 2 show various properties of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3, potential phosphorylation sites; column 4, potential glycosylation sites; column 5, the amino acid residues comprising signature sequences and motifs; column 6,
- 25 homologous sequences; and column 7, analytical methods used to identify each protein through sequence homology and protein motifs.

- The columns of Table 3 show the tissue-specificity and disease-association of nucleotide sequences encoding CSIGP. The first column of Table 3 lists the polynucleotide sequence identifiers. The second column lists tissue categories which express CSIGP as a fraction of total
- 30 tissue categories expressing CSIGP. The third column lists diseases, disorders, and conditions associated with those tissues expressing CSIGP. The fourth column lists the vectors used to subclone the cDNA library.

- The following fragments of the nucleotide sequences encoding CSIGP are useful in hybridization or amplification technologies to identify SEQ ID NO:14-26 and to distinguish
- 35 between SEQ ID NO:14-26 and similar polynucleotide sequences. The useful fragments are the

fragment of SEQ ID NO:14 from about nucleotide 135 to about nucleotide 189, the  
fragment of SEQ ID NO:15 from about nucleotide 493 to about nucleotide 558, the  
fragment of SEQ ID NO:16 from about nucleotide 1170 to about nucleotide 1233, the  
fragment of SEQ ID NO:17 from about nucleotide 939 to about nucleotide 996, the  
5 fragment of SEQ ID NO:18 from about nucleotide 424 to about nucleotide 486, the  
fragment of SEQ ID NO:19 from about nucleotide 274 to about nucleotide 333, and the  
fragment of SEQ ID NO:20 from about nucleotide 1013 to about nucleotide 1070, the  
fragment of SEQ ID NO:21 from about nucleotide 284 to about nucleotide 325, the fragment of  
SEQ ID NO:22 from about nucleotide 642 to about nucleotide 674, the fragment of SEQ ID  
10 NO:23 from about nucleotide 742 to about nucleotide 769, the fragment of SEQ ID NO:24 from  
about nucleotide 457 to about nucleotide 486, the fragment of SEQ ID NO:25 from about  
nucleotide 205 to about nucleotide 246, and the fragment of SEQ ID NO:26 from about nucleotide  
319 to about nucleotide 342.

The invention also encompasses CSIGP variants. A preferred CSIGP variant is one which  
15 has at least about 80%, more preferably at least about 90%, and most preferably at least about 95%  
amino acid sequence identity to the CSIGP amino acid sequence, and which contains at least one  
functional or structural characteristic of CSIGP.

The invention also encompasses polynucleotides which encode CSIGP. In a particular  
embodiment, the invention encompasses a polynucleotide sequence comprising a sequence  
20 selected from the group consisting of SEQ ID NO:14-26 which encodes CSIGP.

The invention also encompasses a variant of a polynucleotide sequence encoding CSIGP.  
In particular, such a variant polynucleotide sequence will have at least about 70%, more preferably  
at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to the  
polynucleotide sequence encoding CSIGP. A particular aspect of the invention encompasses a  
25 variant of a polynucleotide sequence comprising a sequence selected from the group consisting of  
SEQ ID NO:14-26 which has at least about 70%, more preferably at least about 85%, and most  
preferably at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected  
from the group consisting of SEQ ID NO:14-26. Any one of the polynucleotide variants described  
above can encode an amino acid sequence which contains at least one functional or structural  
30 characteristic of CSIGP

It will be appreciated by those skilled in the art that as a result of the degeneracy of the  
genetic code, a multitude of polynucleotide sequences encoding CSIGP, some bearing minimal  
similarity to the polynucleotide sequences of any known and naturally occurring gene, may be  
produced. Thus, the invention contemplates each and every possible variation of polynucleotide

sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring CSIGP, and all such variations are to be considered as being specifically disclosed.

5        Although nucleotide sequences which encode CSIGP and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring CSIGP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding CSIGP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at  
10        which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding CSIGP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally  
15        occurring sequence.

      The invention also encompasses production of DNA sequences which encode CSIGP and CSIGP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to  
20        introduce mutations into a sequence encoding CSIGP or any fragment thereof.

      Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO: 14-26 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.*  
25        152:507-511.) For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide,  
30        and most preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are  
35        accomplished by combining these various conditions as needed. In a preferred embodiment,

hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 µg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50 % formamide, and 200 µg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

The washing steps which follow hybridization can also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include temperature of at least about 25°C, more preferably of at least about 42°C, and most preferably of at least about 68°C. In a preferred embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a most preferred embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art.

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the HYDRA microdispenser (Robbins Scientific, Sunnyvale CA), MICROLAB 2200 (Hamilton, Reno NV), Peltier Thermal Cycler 200 (PTC200; MJ Research, Watertown MA) and the ABI CATALYST 800 (Perkin-Elmer). Sequencing is then carried out using either ABI 373 or 377 DNA Sequencing Systems (Perkin-Elmer) or the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA). The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding CSIGP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect



upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent  
5 directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In  
10 this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-306). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic  
15 DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

20 When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

25 Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal  
30 using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof  
35 which encode CSIGP may be cloned in recombinant DNA molecules that direct expression of

CSIGP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express CSIGP.

5           The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter CSIGP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example,  
10 oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

          In another embodiment, sequences encoding CSIGP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucl.  
15 Acids Res. Symp. Ser. 215-223, and Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232.) Alternatively, CSIGP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of  
20 CSIGP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

          The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by  
25 sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

          In order to express a biologically active CSIGP, the nucleotide sequences encoding CSIGP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted  
30 coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding CSIGP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding CSIGP. Such signals include the ATG initiation codon and adjacent  
35 sequences, e.g. the Kozak sequence. In cases where sequences encoding CSIGP and its initiation

codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous  
5 translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct  
10 expression vectors containing sequences encoding CSIGP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons,  
15 New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding CSIGP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral  
20 expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected  
25 depending upon the use intended for polynucleotide sequences encoding CSIGP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding CSIGP can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or pSPORT1 plasmid (Life Technologies). Ligation of sequences encoding CSIGP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure  
30 for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509.) When large quantities of CSIGP are needed, e.g. for the production of antibodies, vectors which direct high level expression of CSIGP  
35 may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage

promoter may be used.

Yeast expression systems may be used for production of CSIGP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors  
5 direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Grant et al. (1987) *Methods Enzymol.* 153:516-54; and Scorer, C. A. et al. (1994) *Bio/Technology* 12:181-184.)

Plant systems may also be used for expression of CSIGP. Transcription of sequences  
10 encoding CSIGP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell*  
15 *Differ.* 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding CSIGP may be ligated  
20 into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses CSIGP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci.* 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.  
25 SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) *Nat Genet.*  
30 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of CSIGP in cell lines is preferred. For example, sequences encoding CSIGP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate  
35 vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2

days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

- 5 Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* or *apr*<sup>r</sup> cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers
- 10 resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* or *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g.,
- 15 Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech),  $\beta$  glucuronidase and its substrate  $\beta$ -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol.
- 20 Biol. 55:121-131.)

- Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding CSIGP is inserted within a marker gene sequence, transformed cells containing sequences encoding CSIGP can be identified by the absence of marker gene
- 25 function. Alternatively, a marker gene can be placed in tandem with a sequence encoding CSIGP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

- In general, host cells that contain the nucleic acid sequence encoding CSIGP and that express CSIGP may be identified by a variety of procedures known to those of skill in the art.
- 30 These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

- Immunological methods for detecting and measuring the expression of CSIGP using either
- 35 specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques

include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on CSIGP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art.

- 5 (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul MN, Sect. IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols. Humana Press, Totowa NJ).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding CSIGP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding CSIGP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding CSIGP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode CSIGP may be designed to contain signal sequences which direct secretion of CSIGP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to specify protein targeting, folding, and/or activity.

Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC, Bethesda MD) and may be chosen to ensure the

correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding CSIGP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric CSIGP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of CSIGP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the CSIGP encoding sequence and the heterologous protein sequence, so that CSIGP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled CSIGP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract systems (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, preferably <sup>35</sup>S-methionine.

Fragments of CSIGP may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Various fragments of CSIGP may be synthesized separately and then combined to produce the full length molecule.

## THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between CSIGP and cell signaling proteins. In addition, the expression of CSIGP is closely associated with cell proliferation and inflammatory disorders. Therefore, in cell proliferative and

inflammatory disorders where CSIGP is an inhibitor or suppressor of cell proliferation, it is desirable to increase the expression of CSIGP. In cell proliferative and inflammatory disorders where CSIGP is an activator or enhancer and is promoting cell proliferation, it is desirable to decrease the expression of CSIGP.

5           Therefore, in one embodiment, CSIGP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of CSIGP. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria,  
10 polycythemia vera, psoriasis, primary thrombocythemia; cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an inflammatory  
15 disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema  
20 nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis,  
25 thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma.

          In another embodiment, a vector capable of expressing CSIGP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased  
30 expression or activity of CSIGP including, but not limited to, those described above.

          In a further embodiment, a pharmaceutical composition comprising a substantially purified CSIGP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of CSIGP including, but not limited to, those provided above.

35           In still another embodiment, an agonist which modulates the activity of CSIGP may be



administered to a subject to treat or prevent a disorder associated with decreased expression or activity of CSIGP including, but not limited to, those listed above.

In a further embodiment, an antagonist of CSIGP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of CSIGP. Examples of such disorders include, but are not limited to, those described above. In one aspect, an antibody which specifically binds CSIGP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express CSIGP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding CSIGP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of CSIGP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of CSIGP may be produced using methods which are generally known in the art. In particular, purified CSIGP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind CSIGP. Antibodies to CSIGP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies. Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with CSIGP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to

CSIGP have an amino acid sequence consisting of at least about 5 amino acids, and, more preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of

5 CSIGP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to CSIGP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-

10 hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci.* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate

15 antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci.* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce CSIGP-specific single chain antibodies. Antibodies with related specificity, but of distinct

20 idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton D.R. (1991) *Proc. Natl. Acad. Sci.* 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci.* 86:

25 3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299.)

Antibody fragments which contain specific binding sites for CSIGP may also be generated. For example, such fragments include, but are not limited to, F(ab')<sub>2</sub> fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries may be

30 constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) *Science* 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in

35 the art. Such immunoassays typically involve the measurement of complex formation between

CSIGP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering CSIGP epitopes is preferred, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for ABBR. Affinity is expressed as an association constant,  $K_a$ , which is defined as the molar concentration of ABBR-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The  $K_a$  determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple ABBR epitopes, represents the average affinity, or avidity, of the antibodies for ABBR. The  $K_a$  determined for a preparation of monoclonal antibodies, which are monospecific for a particular ABBR epitope, represents a true measure of affinity. High-affinity antibody preparations with  $K_a$  ranging from about  $10^9$  to  $10^{12}$  L/mole are preferred for use in immunoassays in which the ABBR-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with  $K_a$  ranging from about  $10^6$  to  $10^7$  L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of ABBR, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J. E. and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is preferred for use in procedures requiring precipitation of ABBR-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding CSIGP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding CSIGP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding CSIGP. Thus, complementary molecules or fragments may be used to modulate CSIGP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding CSIGP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses,

or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding CSIGP. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

5 Genes encoding CSIGP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding CSIGP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a  
10 month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding CSIGP. Oligonucleotides derived from the transcription  
15 initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al.  
20 (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the  
25 ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding CSIGP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences:  
30 GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

35 Complementary ribonucleic acid molecules and ribozymes of the invention may be

prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding CSIGP. Such DNA sequences may be  
5 incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3'  
10 ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and  
15 uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers  
20 may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

25 An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of CSIGP, antibodies to CSIGP, and mimetics, agonists, antagonists, or inhibitors of CSIGP. The compositions may be administered alone or in combination with at least one other agent, such as a  
30 stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial,  
35 intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal,

enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl

cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the  
5 suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a  
10 manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the  
15 corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an  
20 appropriate container and labeled for treatment of an indicated condition. For administration of CSIGP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the  
25 art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes  
30 for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example CSIGP or fragments thereof, antibodies of CSIGP, and agonists, antagonists or inhibitors of CSIGP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals,  
35 such as by calculating the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population) or

LD<sub>50</sub> (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the LD<sub>50</sub>/ED<sub>50</sub> ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED<sub>50</sub> with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 µg to 100,000 µg, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

#### DIAGNOSTICS

In another embodiment, antibodies which specifically bind CSIGP may be used for the diagnosis of cell proliferative and inflammatory disorders characterized by expression of CSIGP, or in assays to monitor patients being treated with CSIGP or agonists, antagonists, or inhibitors of CSIGP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for CSIGP include methods which utilize the antibody and a label to detect CSIGP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring CSIGP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of CSIGP expression. Normal or standard values for CSIGP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to



CSIGP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of CSIGP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for  
5 diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding CSIGP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of CSIGP  
10 may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of CSIGP, and to monitor regulation of CSIGP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding CSIGP or closely related  
15 molecules may be used to identify nucleic acid sequences which encode CSIGP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will determine whether the probe identifies only naturally occurring sequences encoding CSIGP, allelic variants, or related sequences.

20 Probes may also be used for the detection of related sequences, and should preferably have at least 50% sequence identity to any of the CSIGP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:14-26 or from genomic sequences including promoters, enhancers, and introns of the CSIGP gene.

25 Means for producing specific hybridization probes for DNAs encoding CSIGP include the cloning of polynucleotide sequences encoding CSIGP or CSIGP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a  
30 variety of reporter groups, for example, by radionuclides such as <sup>32</sup>P or <sup>35</sup>S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding CSIGP may be used for the diagnosis of cell proliferative and inflammatory disorders associated with expression of CSIGP. Examples of such disorders include, but are not limited to, a disorder of cell proliferation such as actinic keratosis,  
35 arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease

(MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia; cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease; adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma. The polynucleotide sequences encoding CSIGP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and ELISA assays; and in microarrays utilizing fluids or tissues from patients to detect altered CSIGP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding CSIGP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding CSIGP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding CSIGP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of CSIGP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a

sequence, or a fragment thereof, encoding CSIGP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with  
5 values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results  
10 obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A  
15 more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding CSIGP may involve the use of PCR. These oligomers may be chemically synthesized, generated  
20 enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding CSIGP, or a fragment of a polynucleotide complementary to the polynucleotide encoding CSIGP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantitation of closely related DNA or RNA sequences.

25 Methods which may also be used to quantitate the expression of CSIGP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format  
30 where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously  
35 and to identify genetic variants, mutations, and polymorphisms. This information may be used to

determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding CSIGP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the location of the gene encoding CSIGP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, CSIGP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of  
5 binding complexes between CSIGP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with CSIGP, or  
10 fragments thereof, and washed. Bound CSIGP is then detected by methods well known in the art. Purified CSIGP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which  
15 neutralizing antibodies capable of binding CSIGP specifically compete with a test compound for binding CSIGP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with CSIGP.

In additional embodiments, the nucleotide sequences which encode CSIGP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely  
20 on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of  
25 the remainder of the disclosure in any way whatsoever.

The entire disclosure of all applications, patents, and publications, cited above and below, and of US provisional applications 60/085,343 (filed May 13, 1998), and 60/098,010 (filed August 26, 1998) are hereby incorporated by reference.

### EXAMPLES

#### 30 I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting  
35 lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated

from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A<sup>+</sup>) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Valencia CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6). Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), pSPORT1 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 $\alpha$ , DH10B, or ElectroMAX DH10B from Life Technologies.

## II. Isolation of cDNA Clones

Plasmids were recovered from host cells by in vivo excision, using the UNIZAP vector system (Stratagene) or cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the REAL Prep 96 plasmid kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a Fluoroskan II

fluorescence scanner (Labsystems Oy, Helsinki, Finland).

### III. Sequencing and Analysis

The cDNAs were prepared for sequencing using either an ABI CATALYST 800 (Perkin-Elmer) or a HYDRA microdispenser (Robbins) or MICROLAB 2200 (Hamilton) sequencing  
5 preparation system in combination with PTC-200 thermal cyclers (MJ Research). The cDNAs  
were sequenced using the ABI PRISM 373 or 377 sequencing systems of the MEGABACE 1000  
DNA sequencing system (Molecular Dynamics) and ABI protocols, base calling software, and kits  
(Perkin-Elmer). Alternatively, solutions and dyes from Amersham Pharmacia Biotech were used.  
Reading frames were determined using standard methods (Ausubel, 1997, supra). Some of the  
10 cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA, extension, and shotgun sequencing  
were assembled and analyzed using a combination of software programs which utilize algorithms  
well known to those skilled in the art. Table 5 summarizes the software programs, descriptions,  
references, and threshold parameters used. The first column of Table 5 shows the tools, programs,  
15 and algorithms used, the second column provides a brief description thereof, the third column  
presents the references which are incorporated by reference herein, and the fourth column  
presents, where applicable, the scores, probability values, and other parameters used to evaluate  
the strength of a match between two sequences (the higher the probability the greater the  
homology). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software  
20 Engineering, S. San Francisco CA) and LASERGENE software (DNASTAR).

cDNAs were also compared to sequences in GenBank using a search algorithm developed  
by Applied Biosystems and incorporated into the INHERIT™ 670 sequence analysis system. In  
this algorithm, Pattern Specification Language (TRW Inc, Los Angeles, CA) was used to  
determine regions of homology. The three parameters that determine how the sequence  
25 comparisons run were window size, window offset, and error tolerance. Using a combination of  
these three parameters, the DNA database was searched for sequences containing regions of  
homology to the query sequence, and the appropriate sequences were scored with an initial value.  
Subsequently, these homologous regions were examined using dot matrix homology plots to  
distinguish regions of homology from chance matches. Smith-Waterman alignments were used to  
30 display the results of the homology search.

Peptide and protein sequence homologies were ascertained using the INHERIT- 670  
sequence analysis system using the methods similar to those used in DNA sequence homologies.  
Pattern Specification Language and parameter windows were used to search protein databases for  
sequences containing regions of homology which were scored with an initial value. Dot-matrix  
35 homology plots were examined to distinguish regions of significant homology from chance

matches.

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then  
 5 queried against a selection of public databases such as GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS to acquire annotation, using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length  
 10 polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, PFAM, and Prosite.

The programs described above for the assembly and analysis of full length polynucleotide  
 15 and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:14-26. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

#### IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a  
 20 gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ database (Incyte  
 25 Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

100

30 The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

35 The results of northern analyses are reported a percentage distribution of libraries in which



the transcript encoding CSIGP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease or condition categories included cancer,

- 5 inflammation/trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease expression are reported in Table 3.

#### V. Extension of CSIGP Encoding Polynucleotides

- 10 The full length nucleic acid sequence of SEQ ID NO:14-26 was produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about  
15 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structure and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

- 20 High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing  $Mg^{2+}$ ,  $(NH_4)_2SO_4$ , and  $\beta$ -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the  
25 following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

- 30 The concentration of DNA in each well was determined by dispensing 100  $\mu$ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5  $\mu$ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the  
35 sample and to quantify the concentration of DNA. A 5  $\mu$ l to 10  $\mu$ l aliquot of the reaction mixture

was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For 5 shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in 10 restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following 15 parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were 20 diluted with 20% dimethylsulphoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequence of SEQ ID NO:14-26 is used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

## 25 VI. Choice, Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:14-26 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 30 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 µCi of [ $\gamma$ -<sup>32</sup>P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10<sup>7</sup> counts per minute of the labeled probe is used in a typical membrane- 35 based hybridization analysis of human genomic DNA digested with one of the following

endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature  
5 under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT-AR film (Eastman Kodak, Rochester NY) is exposed to the blots to film for several hours, hybridization patterns are compared visually.

#### VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array  
10 elements on the surface of a substrate. (See, e.g., Baldeschweiler, *supra*.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels  
15 and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected  
20 using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g.,  
25 Schena, M. et al. (1995) *Science* 270:467-470; Shalon, D. et al. (1996) *Genome Res.* 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

#### VIII. Complementary Polynucleotides

Sequences complementary to the CSIGP-encoding sequences, or any parts thereof, are  
30 used to detect, decrease, or inhibit expression of naturally occurring CSIGP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of CSIGP. To inhibit transcription, a complementary oligonucleotide is designed from the most  
35 unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit

translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the CSIGP-encoding transcript.

#### IX. Expression of CSIGP

Expression and purification of CSIGP is achieved using bacterial or virus-based expression systems. For expression of CSIGP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express CSIGP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of CSIGP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding CSIGP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, CSIGP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from CSIGP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch 10 and 16). Purified CSIGP obtained by these methods can be used directly in the following activity assay.

#### X. Demonstration of CSIGP Activity

CSIGP activity can be assayed in vitro by monitoring the mobilization of  $Ca^{++}$  as part of the signal transduction pathway. (See, e.g., Grynkievycz, G. et al. (1985) J. Biol. Chem.

260:3440; McColl, S. et al. (1993) J. Immunol. 150:4550-4555; and Ausel, C. et al. (1988) supra)

The assay requires preloading neutrophils or T cells with a fluorescent dye such as FURA-2 or BCECF (Universal Imaging Corp, Westchester PA) whose emission characteristics have been altered by  $\text{Ca}^{++}$  binding. When the cells are exposed to one or more activating stimuli artificially  
5 (ie, anti-CD3 antibody ligation of the T cell receptor) or physiologically (ie, by allogeneic stimulation),  $\text{Ca}^{++}$  flux takes place. This flux can be observed and quantified by assaying the cells in a fluorometer or fluorescent activated cell sorter. Measurements of  $\text{Ca}^{++}$  flux are compared between cells in their normal state and those preloaded with CSIGP.

Protein kinase activity in CSIGP is determined by measuring the phosphorylation of a  
10 protein substrate using gamma-labeled  $^{32}\text{P}$ -ATP and quantitation of the incorporated radioactivity using a radioisotope counter. CSIGP is incubated with the protein substrate,  $^{32}\text{P}$ -ATP, and an appropriate kinase buffer. The  $^{32}\text{P}$  incorporated into the product is separated from free  $^{32}\text{P}$ -ATP by electrophoresis and the incorporated  $^{32}\text{P}$  is counted. The amount of  $^{32}\text{P}$  recovered is proportional to the activity of CSIGP in the assay. A determination of the specific amino acid residue  
15 phosphorylated is made by phosphoamino acid analysis of the hydrolyzed protein.

Protein phosphatase (PP) activity in CSIGP is determined by measuring the hydrolysis of P-nitrophenyl phosphate (PNPP). CSIGP is incubated together with PNPP in HEPES buffer pH 7.5, in the presence of 0.1% b-mercaptoethanol at 37°C for 60 min. The reaction is stopped by the addition of 6 ml of 10 N NaOH and the increase in light absorbance at 410 nm resulting from the  
20 hydrolysis of PNPP is measured using a spectrophotometer. The increase in light absorbance is proportional to the activity of CSIGP in the assay.

#### **XI. Production of CSIGP Specific Antibodies**

CSIGP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is  
25 used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the CSIGP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are  
30 well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides 15 residues in length are synthesized using an ABI 431A Peptide Synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the  
35 oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for

antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

### **XII. Purification of Naturally Occurring CSIGP Using Specific Antibodies**

Naturally occurring or recombinant CSIGP is substantially purified by immunoaffinity chromatography using antibodies specific for CSIGP. An immunoaffinity column is constructed by covalently coupling anti-CSIGP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing CSIGP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of CSIGP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/CSIGP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and CSIGP is collected.

### **XIII. Identification of Molecules Which Interact with CSIGP**

CSIGP, or biologically active fragments thereof, are labeled with <sup>125</sup>I Bolton-Hunter reagent. (See, e.g., Bolton et al. (1973) Biochem. J. 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled CSIGP, washed, and any wells with labeled CSIGP complex are assayed. Data obtained using different concentrations of CSIGP are used to calculate values for the number, affinity, and association of CSIGP with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table I

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	14	016108	HUVELPB01	016108, 016624, (HUVELPB01), 970134 (MUSCNOT02), 1605858 (LUNGNOT15), 1419046 (KIDNNOT09)
2	15	640521	BRSTNOT03	640521 (BRSTNOT03)
3	16	1250171	LUNGFET03	1250171 (LUNGFET03), 260744 (HNT2RAT01), 077085 (SYNORAB01), 2790184 (COLNTUT16), SAE01398, SAEB00499, SAE02190, SAE00648, SAE00948
4	17	1911587	CONNTUT01	1911587 (CONNTUT01), 1989659 (CORENOT02)
5	18	2079081	ISLTNOT01	2079081 (ISLTNOT01), 2631449 (COLNTUT15), 2350624 (COLSUCT01), 2568459 (HIPOAZT01), 2132860 (OVARNOT03)
6	19	2472655	THP1NOT03	2472655 (THP1NOT03), 1325950 (LPARNOT02), SAEA01014, SAEA01114, SAEA03382
7	20	2948818	KIDNFET01	2948818 (KIDNFET01), 1543592 (PROSTUT04), SAAE00176

Table 1 cont.

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
8	21	054191	FIBRNOT01	054191H1 and 054191R6 (FIBRNOT01), 483547H1, 483547R6, and 483547T6 (HNT2RAT01), 1537974R6 (SINTTUT01), 1633493H1 (COLNNOT19)
9	22	1403604	LATRTUT02	491348H1 (HNT2AGT01), 1403604H1 (LATRTUT02), 3331135T6.com (BRAIFET01), SBAA02561F1.comp, SBAA03200F1, SBAA01960F1.comp, SBAA01439F1, SBAA01304F1
10	23	1652936	PROSTUT08	467767R6 (LATRNOT01), 1551938R6 (PROSNOT06), 1652936F6 and 1652936H1 (PROSTUT08), 1817388F6 and 1817388H1 (PROSNOT20), 2822521H1 (ADRETUT06)
11	24	1710702	PROSNOT16	1474380T1 (LUNGUTUT03), 1710702H1 (PROSNOT16), 2189187H1 (PROSNOT26), 1526267F1 (UCMCL5T01), 1467104F1 (PANCTUT02)
12	25	3239149	COLAUCT01	482693H1 (HNT2RAT01), 2287788R6 (BRAINON01), 2570350T6 (HIPOAZT01), 3239149F6 and 3239149H1 (COLAUCT01), 3837574F6 (DENDTNT01), 4993747H1 (LIVRTUT11)
13	26	3315936	PROSBPT03	2501356T6 (ADRETUT05), 3315936H1 (PROSBPT03)



Table 2

Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential glycosylation sites	Signature Sequence	Homologous Sequence	Analytical Methods
1	418	S359 S2 T12 S56 T91 T257 S287 S306 T402 S414 T9 S16 S43 T87 S184 S327 S334	N54 N70 N118	Y58-I293	Serine /threonine protein kinase	BLOCKS PRINTS PFAM
2	540	S100 T145 S26 T56 S100 T166 S358 S456 T462 T467 S503 S11 S30 S95 S137 S197 T280 T362 S367 S474 Y234 Y305	N460	Y165-V446	Ca2 +/calmodulin- dependent protein kinase kinase	BLOCKS PRINTS MOTIFS BLAST PFAM
3	729	T96 S348 T373 S518 S531 T682 T78 T239 T478 Y235	N42 N455 N614	W9-I238	Serine/ threonine protein kinase	BLOCKS PFAM PRINTS MOTIFS BLAST
4	313	S38 S82 S95 S97 T143 Y30	N79 N80 N172 N192	R114-S135	Protein tyrosine phosphatase	PRINTS BLAST

Table 2 cont.

Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential glycosylation sites	Signature Sequence	Homologous Sequence	Analytical Methods
5	506	S114 S300 S81 S160 T162 S211 S253 S291 S335 S341 T63 S143 T144 S156 T177 S196 S363 S439 Y45 Y187	N275	SH3 domains: R441-L495	PEST phosphatase interacting protein	BLOCKS PRINTS PFAM BLAST
6	341	S39 S118 T125 S180 S110 S170 S173 S195 T299	N37 N178 N229 N263		Prolactin receptor associated protein (PRAP)	BLAST
7	898	S56 T640 S15 S107 T210 T267 S324 S366 S374 S504 T547 T592 T640 S655 T681 T756 S775 S58 S249 T437 S551 T573 S655 T726 T745 T762 S836 S858 S879	N322 N347 N389 N502 N503	F24-V277	Serine/ threonine protein kinase	BLOCKS PRINTS PFAM MOTIFS BLAST

Table 2 cont.

Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential glycosylation sites	Signature Sequence	Homologous Sequence	Analytical Methods
8	336	S34 T110 S148 S311	N137 N144 N169	T175-I195 V236-T254	putative G- protein-coupled receptor	PRINTS, BLAST HMM, Motifs
9	686	T192 S312 S483 S502 S23 T584	N17 N457 N618 N642	G544-N560	GDP-GTP exchange protein	PRINTS, BLAST Motifs
10	519	S3 S77 S130 S176 S187 T196 S245 S265 T280 T290 T305 T324 S325 S351 S384 S390 T29 S33 S265 T305 S311 T453 S464 Y131 Y145	N128		GTPase-interacting protein	BLAST Motifs
11	334	S332 T186 S198 S269 T321 S90 S139 Y289	N20 N30	L267-L281	G-protein beta WD-40 repeat containing protein	PRINTS, BLAST Motifs
12	569	S91 S19 S109 S162 S376 S418 T514 S535 S536 S19 S39 T266 T288 T328 T381 T411 T451 S519	N17 N77 N416	Δ320-V334 M360-M374 I403-T417 V443-I457 I483-L497 I532-F546	beta-transducin repeats containing protein	PRINTS, BLAST PFAM, Motifs
13	123	S14 T107 Y44 Y70	N100	M1-N52	SAR1 family GTP-binding protein	PRINTS, BLOCKS BLAST, Motifs

Table 3

Polynucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
14	Cardiovascular (0.194) Hematopoietic/Immune (0.194) Developmental (0.139)	Cancer (0.389) Inflammation (0.333) Cell proliferative (0.306)	pBLUESCRIPT
15	Reproductive (0.282) Nervous (0.179) Developmental (0.128)	Cancer (0.410) Cell proliferative (0.205) Inflammation (0.154)	pSPORT1
16	Reproductive (0.286) Hematopoietic/Immune (0.167) Nervous (0.119)	Cancer (0.429) Inflammation (0.310) Cell proliferative (0.214)	pINCY
17	Nervous (0.235) Reproductive (0.147) Gastrointestinal (0.118)	Cancer (0.471) Cell proliferative (0.176) Trauma (0.176)	pINCY
18	Reproductive (0.400) Gastrointestinal (0.267) Cardiovascular (0.133)	Cancer (0.533) Inflammation (0.333) Cell proliferative (0.067)	pINCY
19	Nervous (0.273) Hematopoietic/Immune (0.227) Reproductive (0.227)	Cancer (0.364) Inflammation (0.364) Cell proliferative (0.318)	pINCY
20	Hematopoietic/Immune (0.216) Reproductive (0.216) Nervous (0.157)	Cancer (0.412) Inflammation (0.294) Cell proliferative (0.216)	pINCY

Table 3 cont.

Polynucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
21	Cardiovascular (0.217) Gastrointestinal (0.174) Nervous (0.174)	Cell proliferative (0.652) Inflammation (0.304)	pBIUESCRIPT
22	Reproductive (0.370) Nervous (0.222) Hematopoietic/Immune (0.148)	Cell proliferative (0.778) Trauma (0.148)	pINCY
23	Reproductive (0.400) Cardiovascular (0.200) Hematopoietic/Immune (0.133)	Cancer (0.533) Inflammation (0.200)	pINCY
24	Reproductive (0.241) Nervous (0.190) Cardiovascular (0.138)	Cell proliferative (0.724) Inflammation (0.138)	pINCY
25	Musculoskeletal (0.222) Nervous (0.222) Gastrointestinal (0.167)	Cell proliferative (0.555) Inflammation (0.222)	pINCY
26	Reproductive (0.750) Cardiovascular (0.250)	Cancer (0.500) Inflammation (0.500)	pINCY

Table 4

Polynucleotide SEQ ID NO:	Library	Library Description
14	HUVELPB01	The library was constructed using RNA isolated from HUV-EC-C (ATCC CRL 1730) cells that were stimulated with cytokine/LPS. HUV-EC-C is an endothelial cell line derived from the vein of a normal human umbilical cord. RNA was isolated from two pools of HUV-EC-C cells that had been treated with either gamma IFN and TNF-alpha or IL-1 beta and LPS.
15	BRSTNOT03	The library was constructed using RNA isolated from nontumorous breast tissue removed from a 54-year-old Caucasian female during a bilateral radical mastectomy. Pathology for the associated tumor tissue indicated residual invasive grade 3 mammary ductal adenocarcinoma. Family history included benign hypertension, hyperlipidemia, and a malignant neoplasm of the colon.
16	LUNGFET03	The library was constructed using RNA isolated from lung tissue removed from a Caucasian female fetus, who died at 20 weeks' gestation from fetal demise. Family history included bronchitis.
17	CONNTUT01	The library was constructed using RNA isolated from a soft tissue tumor removed from the clival area of the skull of a 30-year-old Caucasian female. Pathology indicated chondroid chordoma with neoplastic cells reactive for keratin. Patient history included deficiency anemia.
18	ISLTNOT01	The library was constructed using RNA isolated from pancreatic islet cells. Starting RNA was made from a pooled collection of islet cells.
19	THP1NOT03	The library was constructed using RNA isolated from untreated THP-1 cells. THP-1 (ATCC TIB 202) is a human promonocyte line derived from the peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia.
20	KIDNFET01	The library was constructed using RNA isolated from kidney tissue removed from a Caucasian female fetus, who died at 17 weeks' gestation from anencephalus. Family history included gastritis.

Table 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Description
21	FIBRN0T01	The library was constructed at Stratagene (SPR937212), using RNA isolated from the WI38 lung fibroblast cell line, which was derived from a 3-month-old Caucasian female fetus. 2x10 <sup>6</sup> primary clones were amplified to stabilize the library for long-term storage.
22	LATRTUT02	The library was constructed using RNA isolated from a myxoma removed from the left atrium of a 43-year-old Caucasian male during annuloplasty. Pathology indicated atrial myxoma. Patient history included pulmonary insufficiency, acute myocardial infarction, atherosclerotic coronary artery disease and hyperlipidemia. Family history included benign hypertension, acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
23	PROSTUT08	The library was constructed using RNA isolated from prostate tumor tissue removed from a 60-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated an adenocarcinoma (Gleason grade 3+4). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Family history included tuberculosis, cerebrovascular disease, and arteriosclerotic coronary artery disease.
24	PROSN0T16	The library was constructed using RNA isolated from diseased prostate tissue removed from a 68-year-old Caucasian male during a radical prostatectomy. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated an adenocarcinoma (Gleason grade 3+4). The patient presented with elevated prostate specific antigen (PSA). During this hospitalization, the patient was diagnosed with myasthenia gravis. Patient history included osteoarthritis, and type II diabetes. Family history included benign hypertension, acute myocardial infarction, hyperlipidemia, and arteriosclerotic coronary artery disease.

Table 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Description
25	COLAUCT01	The library was constructed using RNA isolated from diseased ascending colon tissue removed from a 74-year-old Caucasian male during a multiple-segment large bowel excision with temporary ileostomy. Pathology indicated inflammatory bowel disease consistent with chronic ulcerative colitis, severe acute and chronic mucosal inflammation with erythema, ulceration, and pseudopolyp formation involving the entire colon and rectum. The sigmoid colon had an area of mild stricture formation. One diverticulum with diverticulitis was identified near this zone.
26	PROSBPT03	The library was constructed using RNA isolated from diseased prostate tissue removed from a 59-year-old Caucasian male during a radical prostatectomy and regional lymph node excision. Pathology indicated benign prostatic hyperplasia (BPH). Pathology for the associated tumor indicated adenocarcinoma, Gleason grade 3+3. The patient presented with elevated prostate specific antigen (PSA), benign hypertension, and hyperlipidemia. Family history included cerebrovascular disease, benign hypertension and prostate cancer.



Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value= 1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS and PRINTS databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff, Nucl. Acid Res. 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and Probability value= 1.0E-3 or less, if applicable
PFAM	A Hidden Markov Models-based application useful for protein family search.	Krogh, A. et al. (1994) J. Mol. Biol., 235:1501-1531; Sonnhammer, E.L.L. et al. (1998) Nucleic Acids Res. 26:320-322.	Score=10-50 bits, depending on individual protein families

Table 5 cont.

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221.	Score= 4.0 or greater
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Score=5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch et al. <i>supra</i> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-13, or a fragment thereof.
- 5 2. A substantially purified variant having at least 90% amino acid identity to the amino acid sequence of claim 1.
3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
4. An isolated and purified polynucleotide variant having at least 70% polynucleotide sequence identity to the polynucleotide of claim 3.
- 10 5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
7. A method for detecting a polynucleotide, the method comprising the steps of:
  - 15 (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in the sample, thereby forming a hybridization complex; and
  - (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.
8. The method of claim 7 further comprising amplifying the polynucleotide prior to  
20 hybridization.
9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:14-26, or a fragment thereof.
10. An isolated and purified polynucleotide variant having at least 70% polynucleotide sequence identity to the polynucleotide of claim 9.
- 25 11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.
12. An expression vector comprising at least a fragment of the polynucleotide of claim 3.
13. A host cell comprising the expression vector of claim 12.
- 30 14. A method for producing a polypeptide, the method comprising the steps of:
  - a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and
  - b) recovering the polypeptide from the host cell culture.
15. A pharmaceutical composition comprising the polypeptide of claim 1 in  
35 conjunction with a suitable pharmaceutical carrier.

16. A purified antibody which specifically binds to the polypeptide of claim 1.
17. A purified agonist of the polypeptide of claim 1.
18. A purified antagonist of the polypeptide of claim 1.
19. A method for treating or preventing a disorder associated with decreased  
5 expression of CSIGP, the method comprising administering to a subject in need of such treatment  
an effective amount of the pharmaceutical composition of claim 15.
20. A method for treating or preventing a disorder associated with increased  
expression of CSIGP, the method comprising administering to a subject in need of such treatment  
an effective amount of the antagonist of claim 18.

10

## SEQUENCE LISTING

&lt;110&gt; INCYTE PHARMACEUTICALS, INC.

BANDMAN, Olga  
 HILLMAN, Jennifer L.  
 LAL, Preeti  
 YUE, Henry  
 TANG, Y. Tom  
 PATTERSON, Chandra  
 BAUGHN, Mariah R.  
 YANG, Junming

&lt;120&gt; CELL SIGNALING PROTEINS

&lt;130&gt; PF-0521 PCT

&lt;140&gt; To Be Assigned

&lt;141&gt; Herewith

&lt;150&gt; 60/085,3434; 60/098,010

&lt;151&gt; 1998-05-13; 1998-08-26

&lt;160&gt; 26

&lt;170&gt; PERL Program

&lt;210&gt; 1

&lt;211&gt; 418

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc-feature

&lt;223&gt; Incyte Clone 016108

&lt;400&gt; 1

Met	Ser	Leu	Leu	Asp	Cys	Phe	Cys	Thr	Ser	Arg	Thr	Gln	Val	Glu
1				5					10					15
Ser	Leu	Arg	Pro	Glu	Lys	Gln	Ser	Glu	Thr	Ser	Ile	His	Gln	Tyr
			20						25					30
Leu	Val	Asp	Glu	Pro	Thr	Leu	Ser	Trp	Ser	Arg	Pro	Ser	Thr	Arg
			35						40					45
Ala	Ser	Glu	Val	Leu	Cys	Ser	Thr	Asn	Val	Ser	His	Tyr	Glu	Leu
			50						55					60
Gln	Val	Glu	Ile	Gly	Arg	Gly	Phe	Asp	Asn	Leu	Thr	Ser	Val	His
			65						70					75
Leu	Ala	Arg	His	Thr	Pro	Thr	Gly	Thr	Leu	Val	Thr	Ile	Lys	Ile
			80						85					90
Thr	Asn	Leu	Glu	Asn	Cys	Asn	Glu	Glu	Arg	Leu	Lys	Ala	Leu	Gln
			95						100					105
Lys	Ala	Val	Ile	Leu	Ser	His	Phe	Phe	Arg	His	Pro	Asn	Ile	Thr
			110						115					120
Thr	Tyr	Trp	Thr	Val	Phe	Thr	Val	Gly	Ser	Trp	Leu	Trp	Val	Ile
			125						130					135
Ser	Pro	Phe	Met	Ala	Tyr	Gly	Ser	Ala	Ser	Gln	Leu	Leu	Arg	Thr
			140						145					150
Tyr	Phe	Pro	Glu	Gly	Met	Ser	Glu	Thr	Leu	Ile	Arg	Asn	Ile	Leu
			155						160					165
Phe	Gly	Ala	Val	Arg	Gly	Leu	Asn	Tyr	Leu	His	Gln	Asn	Gly	Cys
			170						175					180
Ile	His	Arg	Ser	Ile	Lys	Ala	Ser	His	Ile	Leu	Ile	Ser	Gly	Asp
			185						190					195
Gly	Leu	Val	Thr	Leu	Ser	Gly	Leu	Ser	His	Leu	His	Ser	Leu	Val

	200		205		210
Lys His Gly Gln Arg	His Arg Ala Val	Tyr Asp Phe Pro Gln Phe			
	215		220		225
Ser Thr Ser Val Gln	Pro Trp Leu Ser	Pro Glu Leu Leu Arg Gln			
	230		235		240
Asp Leu His Gly Leu	Tyr Val Lys Ser	Asp Ile Tyr Ser Val Gly			
	245		250		255
Ile Thr Ala Cys Glu	Leu Ala Ser Gly	Gln Val Pro Phe Gln Asp			
	260		265		270
Met His Arg Thr Gln	Met Leu Leu Gln	Lys Leu Lys Gly Pro Pro			
	275		280		285
Tyr Ser Pro Leu Asp	Ile Ser Ile Phe	Pro Gln Ser Glu Ser Arg			
	290		295		300
Met Lys Asn Ser Gln	Ser Gly Val Asp	Ser Gly Ile Gly Glu Ser			
	305		310		315
Val Leu Val Ser Ser	Gly Thr His Thr	Val Asn Ser Asp Arg Leu			
	320		325		330
His Thr Pro Ser Ser	Lys Thr Phe Ser	Pro Ala Phe Phe Ser Leu			
	335		340		345
Val Gln Leu Cys Leu	Gln Gln Asp Pro	Glu Lys Arg Pro Ser Ala			
	350		355		360
Ser Ser Leu Leu Ser	His Val Phe Phe	Lys Gln Met Lys Glu Glu			
	365		370		375
Ser Gln Asp Ser Ile	Leu Ser Leu Leu	Pro Pro Ala Tyr Asn Lys			
	380		385		390
Pro Ser Ile Ser Leu	Pro Pro Val Leu	Pro Trp Thr Glu Pro Glu			
	395		400		405
Cys Asp Phe Pro Asp	Glu Lys Asp Ser	Tyr Trp Glu Phe			
	410		415		

<210> 2  
 <211> 540  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc-feature  
 <223> Incyte Clone 640521

<400> 2  
 Met Ser Ser Cys Val Ser Ser Gln Pro Ser Ser Asn Arg Ala Ala  
 1 5 10 15  
 Pro Gln Asp Glu Leu Gly Gly Arg Gly Ser Ser Ser Glu Ser  
 20 25 30  
 Gln Lys Pro Cys Glu Ala Leu Arg Gly Leu Ser Ser Leu Ser Ile  
 35 40 45  
 His Leu Gly Met Glu Ser Phe Ile Val Val Thr Glu Cys Glu Pro  
 50 55 60  
 Gly Cys Ala Val Asp Leu Gly Leu Ala Arg Asp Arg Pro Leu Glu  
 65 70 75  
 Ala Asp Gly Gln Glu Val Pro Leu Asp Ser Ser Gly Ser Gln Ala  
 80 85 90  
 Arg Pro His Leu Ser Gly Arg Lys Leu Ser Leu Gln Glu Arg Ser  
 95 100 105  
 Gln Gly Gly Leu Ala Ala Gly Gly Ser Leu Asp Met Asn Gly Arg  
 110 115 120  
 Cys Ile Cys Pro Ser Leu Pro Tyr Ser Pro Val Ser Ser Pro Gln  
 125 130 135  
 Ser Ser Pro Arg Leu Pro Arg Arg Pro Thr Val Glu Ser His His  
 140 145 150  
 Val Ser Ile Thr Gly Met Gln Asp Cys Val Gln Leu Asn Gln Tyr

	155		160		165
Thr Leu Lys Asp	Glu Ile Gly Lys Gly	Ser Tyr Gly Val Val	Lys		
	170		175		180
Leu Ala Tyr Asn	Glu Asn Asp Asn Thr	Tyr Tyr Ala Met Lys	Val		
	185		190		195
Leu Ser Lys Lys	Lys Leu Ile Arg Gln	Ala Gly Phe Pro Arg	Arg		
	200		205		210
Pro Pro Pro Arg	Gly Thr Arg Pro Ala	Pro Gly Gly Cys Ile	Gln		
	215		220		225
Pro Arg Gly Pro	Ile Glu Gln Val Tyr	Gln Glu Ile Ala Ile	Leu		
	230		235		240
Lys Lys Leu Asp	His Pro Asn Val Val	Lys Leu Val Glu Val	Leu		
	245		250		255
Asp Asp Pro Asn	Glu Asp His Leu Tyr	Met Val Phe Glu Leu	Val		
	260		265		270
Asn Gln Gly Pro	Val Met Glu Val Pro	Thr Leu Lys Pro Leu	Ser		
	275		280		285
Glu Asp Gln Ala	Arg Phe Tyr Phe Gln	Asp Leu Ile Lys Gly	Ile		
	290		295		300
Glu Tyr Leu His	Tyr Gln Lys Ile Ile	His Arg Asp Ile Lys	Pro		
	305		310		315
Ser Asn Leu Leu	Val Gly Glu Asp Gly	His Ile Lys Ile Ala	Asp		
	320		325		330
Phe Gly Val Ser	Asn Glu Phe Lys Gly	Ser Asp Ala Leu Leu	Ser		
	335		340		345
Asn Thr Val Gly	Thr Pro Ala Phe Met	Ala Pro Glu Ser Leu	Ser		
	350		355		360
Glu Thr Arg Lys	Ile Phe Ser Gly Lys	Ala Leu Asp Val Trp	Ala		
	365		370		375
Met Gly Val Thr	Leu Tyr Cys Phe Val	Phe Gly Gln Cys Pro	Phe		
	380		385		390
Met Asp Glu Arg	Ile Met Cys Leu His	Ser Lys Ile Lys Ser	Gln		
	395		400		405
Ala Leu Glu Phe	Pro Asp Gln Pro Asp	Ile Ala Glu Asp Leu	Lys		
	410		415		420
Asp Leu Ile Thr	Arg Met Leu Asp Lys	Asn Pro Glu Ser Arg	Ile		
	425		430		435
Val Val Pro Glu	Ile Lys Leu His Pro	Trp Val Thr Arg His	Gly		
	440		445		450
Ala Glu Pro Leu	Pro Ser Glu Asp Glu	Asn Cys Thr Leu Val	Glu		
	455		460		465
Val Thr Glu Glu	Glu Val Glu Asn Ser	Val Lys His Ile Pro	Ser		
	470		475		480
Leu Ala Thr Val	Ile Leu Val Lys Thr	Met Ile Arg Lys Arg	Ser		
	485		490		495
Phe Gly Asn Pro	Phe Glu Gly Ser Arg	Arg Glu Glu Arg Ser	Leu		
	500		505		510
Ser Ala Pro Gly	Asn Leu Leu Thr Lys	Gln Gly Ser Glu Asp	Asn		
	515		520		525
Leu Gln Gly Thr	Asp Pro Pro Pro Val	Gly Glu Glu Glu Val	Leu		
	530		535		540

<210> 3  
 <211> 729  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc-feature  
 <223> Incyte Clone 1250171

&lt;400&gt; 3

```

Met Gln Ser Thr Ser Asn His Leu Trp Leu Leu Ser Asp Ile Leu
 1      5      10
Gly Gln Gly Ala Thr Ala Asn Val Phe Arg Gly Arg His Lys Lys
 20      25      30
Thr Gly Asp Leu Phe Ala Ile Lys Val Phe Asn Asn Ile Ser Phe
 35      40      45
Leu Arg Pro Val Asp Val Gln Met Arg Glu Phe Glu Val Leu Lys
 50      55      60
Lys Leu Asn His Lys Asn Ile Val Lys Leu Phe Ala Ile Glu Glu
 65      70      75
Glu Thr Thr Thr Arg His Lys Val Leu Ile Met Glu Phe Cys Pro
 80      85      90
Cys Gly Ser Leu Tyr Thr Val Leu Glu Glu Pro Ser Asn Ala Tyr
 95      100     105
Gly Leu Pro Glu Ser Glu Phe Leu Ile Val Leu Arg Asp Val Val
 110     115     120
Gly Gly Met Asn His Leu Arg Glu Asn Gly Ile Val His Arg Asp
 125     130     135
Ile Lys Pro Gly Asn Ile Met Arg Val Ile Gly Glu Asp Gly Gln
 140     145     150
Ser Val Tyr Lys Leu Thr Asp Phe Gly Ala Ala Arg Glu Leu Glu
 155     160     165
Asp Asp Glu Gln Phe Val Ser Leu Tyr Gly Thr Glu Glu Tyr Leu
 170     175     180
His Pro Asp Met Tyr Glu Arg Ala Val Leu Arg Lys Asp His Gln
 185     190     195
Lys Lys Tyr Gly Ala Thr Val Asp Leu Trp Ser Ile Gly Val Thr
 200     205     210
Phe Tyr His Ala Ala Thr Gly Ser Leu Pro Phe Arg Pro Phe Glu
 215     220     225
Gly Pro Arg Arg Asn Lys Glu Val Met Tyr Lys Ile Ile Thr Gly
 230     235     240
Lys Pro Ser Gly Ala Ile Ser Gly Val Gln Lys Ala Glu Asn Gly
 245     250     255
Pro Ile Asp Trp Ser Gly Asp Met Pro Val Ser Cys Ser Leu Ser
 260     265     270
Arg Gly Leu Gln Val Leu Leu Thr Pro Val Leu Ala Asn Ile Leu
 275     280     285
Glu Ala Asp Gln Glu Lys Cys Trp Gly Phe Asp Gln Phe Phe Ala
 290     295     300
Glu Thr Ser Asp Ile Leu His Arg Met Val Ile His Val Phe Ser
 305     310     315
Leu Gln Gln Met Thr Ala His Lys Ile Tyr Ile His Ser Tyr Asn
 320     325     330
Thr Ala Thr Ile Phe His Glu Leu Val Tyr Lys Gln Thr Lys Ile
 335     340     345
Ile Ser Ser Asn Gln Glu Leu Ile Tyr Glu Gly Arg Arg Leu Val
 350     355     360
Leu Glu Pro Gly Arg Leu Ala Gln His Phe Pro Lys Thr Thr Glu
 365     370     375
Glu Asn Pro Ile Phe Val Val Ser Arg Glu Pro Leu Asn Thr Ile
 380     385     390
Gly Leu Ile Tyr Glu Lys Ile Ser Leu Pro Lys Val His Pro Arg
 395     400     405
Tyr Asp Leu Asp Gly Asp Ala Ser Met Ala Lys Ala Ile Thr Gly
 410     415     420
Val Val Cys Tyr Ala Cys Arg Ile Ala Ser Thr Leu Leu Leu Tyr
 425     430     435
Gln Glu Leu Met Arg Lys Gly Ile Arg Trp Leu Ile Glu Leu Ile
 440     445     450
Lys Asp Asp Tyr Asn Glu Thr Val His Lys Lys Thr Glu Val Val
 455     460     465
Ile Thr Leu Asp Phe Cys Ile Arg Asn Ile Glu Lys Thr Val Lys

```



470	475	480
Val Tyr Glu Lys Leu Met Lys Ile Asn	Leu Glu Ala Ala Glu Leu	
485	490	495
Gly Glu Ile Ser Asp Ile His Thr Lys	Leu Leu Arg Leu Ser Ser	
500	505	510
Ser Gln Gly Thr Ile Glu Thr Ser Leu	Gln Asp Ile Asp Ser Arg	
515	520	525
Leu Ser Pro Gly Gly Ser Leu Ala Asp	Ala Trp Ala His Gln Glu	
530	535	540
Gly Thr His Pro Lys Asp Arg Asn Val	Glu Lys Leu Gln Val Leu	
545	550	555
Leu Asn Cys Met Thr Glu Ile Tyr Tyr	Gln Phe Lys Lys Asp Lys	
560	565	570
Ala Glu Arg Arg Leu Ala Tyr Asn Glu	Glu Gln Ile His Lys Phe	
575	580	585
Asp Lys Gln Lys Leu Tyr Tyr His Ala	Thr Lys Ala Met Thr His	
590	595	600
Phe Thr Asp Glu Cys Val Lys Lys Tyr	Glu Ala Phe Leu Asn Lys	
605	610	615
Ser Glu Glu Trp Ile Arg Lys Met Leu	His Leu Arg Lys Gln Leu	
620	625	630
Leu Ser Leu Thr Asn Gln Cys Phe Asp	Ile Glu Glu Glu Val Ser	
635	640	645
Lys Tyr Gln Glu Tyr Thr Asn Glu Leu	Gln Glu Thr Leu Pro Gln	
650	655	660
Lys Met Phe Thr Ala Ser Ser Gly Ile	Lys His Thr Met Thr Pro	
665	670	675
Ile Tyr Pro Ser Ser Asn Thr Leu Val	Glu Met Thr Leu Gly Met	
680	685	690
Lys Lys Leu Lys Glu Glu Met Glu Gly	Val Val Lys Glu Leu Ala	
695	700	705
Glu Asn Asn His Ile Leu Glu Arg Phe	Gly Ser Leu Thr Met Asp	
710	715	720
Gly Gly Leu Arg Asn Val Asp Cys Leu		
725		

<210> 4  
 <211> 313  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc-feature  
 <223> Incyte Clone 1911587

<400> 4  
 Met Pro Gly Leu Leu Leu Cys Glu Pro Thr Glu Leu Tyr Asn Ile  
 1 5 10 15  
 Leu Asn Gln Ala Thr Lys Leu Ser Arg Leu Thr Asp Pro Asn Tyr  
 20 25 30  
 Leu Cys Leu Leu Asp Val Arg Ser Lys Trp Glu Tyr Asp Glu Ser  
 35 40 45  
 His Val Ile Thr Ala Leu Arg Val Lys Lys Lys Asn Asn Glu Tyr  
 50 55 60  
 Leu Leu Pro Glu Ser Val Asp Leu Glu Cys Val Lys Tyr Cys Val  
 65 70 75  
 Val Tyr Asp Asn Asn Ser Ser Thr Leu Glu Ile Leu Leu Lys Asp  
 80 85 90  
 Asp Asp Asp Asp Ser Asp Ser Asp Gly Asp Gly Lys Asp Leu Val  
 95 100 105  
 Pro Gln Ala Ala Ile Glu Tyr Gly Arg Ile Leu Thr Arg Leu Thr

	110		115		120
His His Pro Val Tyr	Ile Leu Lys Gly	Gly Tyr Glu Arg Phe	Ser		
	125		130		135
Gly Thr Tyr His Phe	Leu Arg Thr Gln	Lys Ile Ile Trp Met	Pro		
	140		145		150
Gln Glu Leu Asp Ala	Phe Gln Pro Tyr	Pro Ile Glu Ile Val	Pro		
	155		160		165
Gly Lys Val Phe Val	Gly Asn Phe Ser	Gln Ala Cys Asp Pro	Lys		
	170		175		180
Ile Gln Lys Asp Leu	Lys Ile Lys Ala	His Val Asn Val Ser	Met		
	185		190		195
Asp Thr Gly Pro Phe	Phe Ala Gly Asp	Ala Asp Arg Leu Leu	His		
	200		205		210
Ile Arg Ile Glu Asp	Ser Pro Glu Ala	Gln Ile Leu Pro Phe	Leu		
	215		220		225
Arg His Met Cys His	Phe Ile Glu Ile	His His His Leu Gly	Ser		
	230		235		240
Val Ile Leu Ile Phe	Ser Thr Gln Gly	Ile Ser Arg Ser Cys	Ala		
	245		250		255
Ala Ile Ile Ala Tyr	Leu Met His Ser	Asn Glu Gln Thr Leu	Gln		
	260		265		270
Arg Ser Trp Ala Tyr	Val Lys Lys Cys	Lys Asn Asn Met Cys	Pro		
	275		280		285
Asn Arg Gly Leu Val	Ser Gln Leu Leu	Glu Trp Glu Lys Thr	Ile		
	290		295		300
Leu Gly Asp Ser Ile	Thr Asn Ile Met	Asp Pro Leu Tyr			
	305		310		

&lt;210&gt; 5

&lt;211&gt; 506

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc-feature

&lt;223&gt; Incyte Clone 2079081

&lt;400&gt; 5

Met Arg Asp Pro Leu	Thr Asp Cys Pro Tyr	Asn Lys Val Tyr Lys		
1	5	10	15	
Asn Leu Lys Glu Phe	Ser Gln Asn Gly Glu	Asn Phe Cys Lys Gln		
	20	25	30	
Val Thr Ser Val Leu	Gln Gln Arg Ala Asn	Leu Glu Ile Ser Tyr		
	35	40	45	
Ala Lys Gly Leu Gln	Lys Leu Ala Ser Lys	Leu Ser Lys Ala Leu		
	50	55	60	
Gln Asn Thr Arg Lys	Ser Cys Val Ser Ser	Ala Trp Ala Trp Ala		
	65	70	75	
Ser Glu Gly Met Lys	Ser Thr Ala Asp Leu	His Gln Lys Leu Gly		
	80	85	90	
Lys Ala Ile Glu Leu	Glu Ala Ile Lys Pro	Thr Tyr Gln Val Leu		
	95	100	105	
Asn Val Gln Glu Lys	Lys Arg Lys Ser Leu	Asp Asn Glu Val Glu		
	110	115	120	
Lys Thr Ala Asn Leu	Val Ile Ser Asn Trp	Asn Gln Gln Ile Lys		
	125	130	135	
Ala Lys Lys Lys Leu	Met Val Ser Thr Lys	Lys His Glu Ala Leu		
	140	145	150	
Phe Gln Leu Val Glu	Ser Ser Lys Gln Ser	Met Thr Glu Lys Glu		
	155	160	165	
Lys Arg Lys Leu Leu	Asn Lys Leu Thr Lys	Ser Thr Glu Lys Leu		

	170		175		180
Glu Lys Glu Asp	Glu Asn Tyr Tyr Gln	Lys Asn Met Ala Gly Tyr			
	185		190		195
Ser Thr Arg Leu	Lys Trp Glu Asn Thr	Leu Glu Asn Cys Tyr Gln			
	200		205		210
Ser Ile Leu Glu	Leu Glu Lys Glu Arg	Ile Gln Leu Leu Cys Asn			
	215		220		225
Asn Leu Asn Gln	Tyr Ser Gln His Ile	Ser Leu Phe Gly Gln Thr			
	230		235		240
Leu Thr Thr Cys	His Thr Gln Ile His	Cys Ala Ile Ser Lys Ile			
	245		250		255
Asp Ile Glu Lys	Asp Ile Gln Ala Val	Met Glu Glu Thr Ala Ile			
	260		265		270
Leu Ser Thr Glu	Asn Lys Ser Glu Phe	Leu Leu Thr Asp Tyr Phe			
	275		280		285
Glu Glu Asp Pro	Asn Ser Ala Met Asp	Lys Glu Arg Arg Lys Ser			
	290		295		300
Leu Leu Lys Pro	Lys Leu Leu Arg Leu	Gln Arg Asp Ile Glu Lys			
	305		310		315
Ala Ser Lys Asp	Lys Glu Gly Leu Glu	Arg Met Leu Lys Thr Tyr			
	320		325		330
Ser Ser Thr Ser	Ser Phe Ser Asp Ala	Lys Ser Gln Lys Asp Thr			
	335		340		345
Ala Ala Leu Met	Asp Glu Asn Asn Leu	Lys Leu Asp Leu Leu Glu			
	350		355		360
Ala Asn Ser Tyr	Lys Leu Ser Ser Met	Leu Ala Glu Leu Glu Gln			
	365		370		375
Arg Pro Gln Pro	Ser His Pro Cys Ser	Asn Ser Ile Phe Arg Trp			
	380		385		390
Arg Glu Lys Glu	His Thr His Ser Tyr	Val Lys Ile Ser Arg Pro			
	395		400		405
Phe Leu Met Lys	Arg Leu Glu Asn Ile	Val Ser Lys Ala Ser Ser			
	410		415		420
Gly Gly Gln Ser	Asn Pro Gly Ser Ser	Thr Pro Ala Pro Gly Ala			
	425		430		435
Ala Gln Leu Ser	Ser Arg Leu Cys Lys	Ala Leu Tyr Ser Phe Gln			
	440		445		450
Ala Arg Gln Asp	Asp Glu Leu Asn Leu	Glu Lys Gly Asp Ile Val			
	455		460		465
Ile Ile His Glu	Lys Lys Glu Glu Gly	Trp Trp Phe Gly Ser Leu			
	470		475		480
Asn Gly Lys Lys	Gly His Phe Pro Ala	Ala Tyr Val Glu Glu Leu			
	485		490		495
Pro Ser Asn Ala	Gly Asn Thr Ala Thr	Lys Ala			
	500		505		

&lt;210&gt; 6

&lt;211&gt; 341

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc-feature

&lt;223&gt; Incyte Clone 2472655

&lt;400&gt; 6

Met Arg Lys Val Val Leu Ile Thr Gly Ala Ser Ser Gly Ile Gly			
1	5	10	15
Leu Ala Leu Cys Lys Arg Leu Leu Ala Glu Asp Asp Glu Leu His			
20	25		30
Leu Cys Leu Ala Cys Arg Asn Met Ser Lys Ala Glu Ala Val Cys			

```

35          40          45
Ala Ala Leu Leu Ala Ser His Pro Thr Ala Glu Val Thr Ile Val
50          55          60
Gln Val Asp Val Ser Asn Leu Gln Ser Val Phe Arg Ala Ser Lys
65          70          75
Glu Leu Lys Gln Arg Phe Gln Arg Leu Asp Cys Ile Tyr Leu Asn
80          85          90
Ala Gly Ile Met Pro Asn Pro Gln Leu Asn Ile Lys Ala Leu Phe
95          100         105
Phe Gly Leu Phe Ser Arg Lys Val Ile His Met Phe Ser Thr Ala
110         115         120
Glu Gly Leu Leu Thr Gln Gly Asp Lys Ile Thr Ala Asp Gly Leu
125         130         135
Gln Glu Val Phe Glu Thr Asn Val Phe Gly His Phe Ile Leu Ile
140         145         150
Arg Glu Leu Glu Pro Leu Leu Cys His Ser Asp Asn Pro Ser Gln
155         160         165
Leu Ile Trp Thr Ser Ser Arg Ser Ala Arg Lys Ser Asn Phe Ser
170         175         180
Leu Glu Asp Phe Gln His Ser Lys Gly Lys Glu Pro Tyr Ser Ser
185         190         195
Ser Lys Tyr Ala Thr Asp Leu Leu Ser Val Ala Leu Asn Arg Asn
200         205         210
Phe Asn Gln Gln Gly Leu Tyr Ser Asn Val Ala Cys Pro Gly Thr
215         220         225
Ala Leu Thr Asn Leu Thr Tyr Gly Ile Leu Pro Pro Phe Ile Trp
230         235         240
Thr Leu Leu Met Pro Ala Ile Leu Leu Leu Arg Phe Phe Ala Asn
245         250         255
Ala Phe Thr Leu Thr Pro Tyr Asn Gly Thr Glu Ala Leu Val Trp
260         265         270
Leu Phe His Gln Lys Pro Glu Ser Leu Asn Pro Leu Ile Lys Tyr
275         280         285
Leu Ser Ala Thr Thr Gly Phe Gly Arg Asn Tyr Ile Met Thr Gln
290         295         300
Lys Met Asp Leu Asp Glu Asp Thr Ala Glu Lys Phe Tyr Gln Lys
305         310         315
Leu Leu Glu Leu Glu Lys His Ile Arg Val Thr Ile Gln Lys Thr
320         325         330
Asp Asn Gln Ala Arg Leu Ser Gly Ser Cys Leu
335         340

```

&lt;210&gt; 7

&lt;211&gt; 898

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc-feature

&lt;223&gt; Incyte Clone 2948818

&lt;400&gt; 7

```

Met Arg Lys Gly Val Leu Lys Asp Pro Glu Ile Ala Asp Leu Ser
1      5      10      15
Tyr Lys Asp Asp Pro Glu Glu Leu Phe Ile Gly Leu His Glu Ile
20     25     30
Gly His Gly Ser Phe Gly Ala Val Tyr Phe Ala Thr Asn Ala His
35     40     45
Thr Ser Glu Val Val Ala Ile Lys Lys Met Ser Tyr Ser Gly Lys
50     55     60
Gln Thr His Glu Lys Trp Gln Asp Ile Leu Lys Glu Val Lys Phe

```

	65		70		75
Leu Arg Gln Leu Lys	His Pro Asn Thr	Ile Glu Tyr Lys Gly Cys			
	80		85		90
Tyr Leu Lys Glu His	Thr Ala Trp Leu	Val Met Glu Tyr Cys Leu			
	95		100		105
Gly Ser Ala Ser Asp	Leu Leu Glu Val	His Lys Lys Pro Leu Gln			
	110		115		120
Glu Val Glu Ile Ala	Ile Thr His	Gly Ala Leu His Gly Leu			
	125		130		135
Ala Tyr Leu His Ser	His Ala Leu Ile	His Arg Asp Ile Lys Ala			
	140		145		150
Gly Asn Ile Leu Thr	Glu Pro Gly	Gln Val Lys Leu Ala Asp			
	155		160		165
Phe Gly Ser Ala Ser	Met Ala Ser Pro	Ala Asn Ser Phe Val Gly			
	170		175		180
Thr Pro Tyr Trp Met	Ala Pro Glu Val	Ile Leu Ala Met Asp Glu			
	185		190		195
Gly Gln Tyr Asp Gly	Lys Val Asp Ile	Trp Ser Leu Gly Ile Thr			
	200		205		210
Cys Ile Glu Leu Ala	Glu Arg Lys Pro	Pro Leu Phe Asn Met Asn			
	215		220		225
Ala Met Ser Ala Leu	Tyr His Ile Ala	Gln Asn Asp Ser Pro Thr			
	230		235		240
Leu Gln Ser Asn Glu	Trp Thr Asp Ser	Phe Arg Arg Phe Val Asp			
	245		250		255
Tyr Cys Leu Gln Lys	Ile Pro Gln Glu	Arg Pro Thr Ser Ala Glu			
	260		265		270
Leu Leu Arg His Asp	Phe Val Arg Arg	Asp Arg Pro Leu Arg Val			
	275		280		285
Leu Ile Asp Leu Ile	Gln Arg Thr Lys	Asp Ala Val Arg Glu Leu			
	290		295		300
Asp Asn Leu Gln Tyr	Arg Lys Met Lys	Lys Ile Leu Phe Glu Glu			
	305		310		315
Thr Arg Asn Gly Pro	Leu Asn Glu Ser	Gln Glu Asp Glu Glu Asp			
	320		325		330
Ser Glu His Gly Thr	Ser Leu Asn Arg	Glu Met Asp Ser Leu Gly			
	335		340		345
Ser Asn His Ser Ile	Pro Ser Met Ser	Val Ser Thr Gly Ser Gln			
	350		355		360
Ser Ser Ser Val Asn	Ser Met Gln Glu	Val Met Asp Glu Ser Ser			
	365		370		375
Ser Glu Leu Val Met	Met His Asp Asp	Glu Ser Thr Ile Asn Ser			
	380		385		390
Ser Ser Ser Val Val	His Lys Lys Asp	His Val Phe Ile Arg Asp			
	395		400		405
Glu Ala Gly His Gly	Asp Pro Arg Pro	Glu Pro Arg Pro Thr Gln			
	410		415		420
Ser Val Gln Ser Gln	Ala Leu His Tyr	Arg Asn Arg Glu Arg Phe			
	425		430		435
Ala Thr Ile Lys Ser	Ala Ser Leu Val	Thr Arg Gln Ile His Glu			
	440		445		450
His Glu Gln Glu Asn	Glu Leu Arg Glu	Gln Met Ser Gly Tyr Lys			
	455		460		465
Arg Met Arg Arg Gln	His Gln Lys Gln	Leu Ile Ala Leu Glu Asn			
	470		475		480
Lys Leu Lys Ala Glu	Met Asp Glu His	Arg Leu Lys Leu Gln Lys			
	485		490		495
Glu Val Glu Thr His	Ala Asn Asn Ser	Ser Ile Glu Leu Glu Lys			
	500		505		510
Leu Ala Lys Lys Gln	Val Ala Ile Ile	Glu Lys Glu Ala Lys Val			
	515		520		525
Ala Ala Ala Asp Glu	Lys Lys Phe Gln	Gln Ile Leu Ala Gln			
	530		535		540
Gln Lys Lys Asp Leu	Thr Thr Phe Leu	Glu Ser Gln Lys Lys Gln			

	545		550		555
Tyr Lys Ile Cys	Lys Glu Lys Ile Lys	Glu Glu Met Asn Glu	Asp		
	560		565		570
His Ser Thr Pro	Lys Lys Glu Lys Gln	Glu Arg Ile Ser Lys	His		
	575		580		585
Lys Glu Asn Leu	Gln His Thr Gln Ala	Glu Glu Glu Ala His	Leu		
	590		595		600
Leu Thr Gln Gln	Arg Leu Tyr Tyr Asp	Lys Asn Cys Arg Phe	Phe		
	605		610		615
Lys Arg Lys Ile	Met Ile Lys Arg His	Glu Val Glu Gln Gln	Asn		
	620		625		630
Ile Arg Glu Glu	Leu Asn Lys Lys Arg	Thr Gln Lys Glu Met	Glu		
	635		640		645
His Ala Met Leu	Ile Arg His Asp Glu	Ser Thr Arg Glu Leu	Glu		
	650		655		660
Tyr Arg Gln Leu	His Thr Leu Gln Lys	Leu Arg Met Asp Leu	Ile		
	665		670		675
Arg Leu Gln His	Gln Thr Glu Leu Glu	Asn Gln Leu Glu Tyr	Asn		
	680		685		690
Lys Arg Arg Glu	Arg Glu Leu His Arg	Lys His Val Met Glu	Leu		
	695		700		705
Arg Gln Gln Pro	Lys Asn Leu Lys Ala	Met Glu Met Gln Ile	Lys		
	710		715		720
Lys Gln Phe Gln	Asp Thr Cys Lys Val	Gln Thr Lys Gln Tyr	Lys		
	725		730		735
Ala Leu Lys Asn	His Gln Leu Glu Val	Thr Pro Lys Asn Glu	His		
	740		745		750
Lys Thr Ile Leu	Lys Thr Leu Lys Asp	Glu Gln Thr Arg Lys	Leu		
	755		760		765
Ala Ile Leu Ala	Glu Gln Tyr Glu Gln	Ser Ile Asn Glu Met	Met		
	770		775		780
Ala Ser Gln Ala	Leu Arg Leu Asp Glu	Ala Gln Glu Ala Glu	Cys		
	785		790		795
Gln Ala Leu Arg	Leu Gln Leu Gln Gln	Glu Met Glu Leu Leu	Asn		
	800		805		810
Ala Tyr Gln Ser	Lys Ile Lys Met Gln	Thr Glu Ala Gln His	Glu		
	815		820		825
Arg Glu Leu Gln	Lys Leu Glu Gln Arg	Val Ser Leu Arg Arg	Ala		
	830		835		840
His Leu Glu Gln	Lys Ile Glu Glu Glu	Leu Ala Ala Leu Gln	Lys		
	845		850		855
Glu Arg Ser Glu	Arg Ile Lys Asn Leu	Leu Glu Arg Gln Glu	Arg		
	860		865		870
Glu Ile Glu Thr	Phe Asp Met Glu Ser	Leu Arg Met Gly Phe	Gly		
	875		880		885
Asn Leu Val Thr	Leu Asp Phe Pro Lys	Glu Asp Tyr Arg			
	890		895		

&lt;210&gt; 8

&lt;211&gt; 336

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc-feature

&lt;223&gt; Incyte Clone 054191

&lt;400&gt; 8

Met Ala Thr Leu Ser Val Ile Gly Ser Ser Ser Leu Ile Ala Tyr

1

5

10

15

Ala Val Phe His Asn Ile Gln Lys Ser Pro Glu Ile Arg Pro Leu

```

      20      25      30
Phe Tyr Leu Ser Phe Cys Asp Leu Leu Leu Gly Leu Cys Trp Leu
      35      40      45
Thr Glu Thr Leu Leu Tyr Gly Ala Ser Val Ala Asn Lys Asp Ile
      50      55      60
Ile Cys Tyr Asn Leu Gln Ala Val Gly Gln Ile Phe Tyr Ile Ser
      65      70      75
Ser Phe Leu Tyr Thr Val Asn Tyr Ile Trp Tyr Leu Tyr Thr Glu
      80      85      90
Leu Arg Met Lys His Thr Gln Ser Gly Gln Ser Thr Ser Pro Leu
      95     100     105
Val Ile Asp Tyr Thr Cys Arg Val Gly Gln Met Ala Phe Val Phe
     110     115     120
Ser Ser Leu Ile Pro Leu Leu Leu Met Thr Pro Val Phe Cys Leu
     125     130     135
Gly Asn Thr Ser Gly Cys Phe Gln Asn Phe Ser Gln Ser His Lys
     140     145     150
Cys Ile Leu Met His Ser Pro Pro Ser Ala Met Ala Glu Leu Pro
     155     160     165
Pro Ser Ala Asn Thr Ser Val Cys Ser Thr Leu Tyr Phe Tyr Gly
     170     175     180
Ile Ala Ile Phe Leu Gly Ser Phe Val Leu Ser Leu Leu Thr Ile
     185     190     195
Met Val Leu Leu Ile Arg Ala Gln Thr Leu Tyr Lys Lys Phe Val
     200     205     210
Lys Ser Thr Gly Phe Leu Gly Ser Glu Gln Trp Ala Val Ile His
     215     220     225
Ile Val Asp Gln Arg Val Arg Phe Tyr Pro Val Ala Phe Phe Cys
     230     235     240
Cys Trp Gly Pro Ala Val Ile Leu Met Ile Ile Lys Leu Thr Lys
     245     250     255
Pro Gln Asp Thr Lys Leu His Met Ala Leu Tyr Val Leu Gln Ala
     260     265     270
Leu Thr Ala Thr Ser Gln Gly Leu Leu Asn Cys Gly Val Tyr Gly
     275     280     285
Trp Thr Gln His Lys Phe His Gln Leu Lys Gln Glu Ala Arg Arg
     290     295     300
Asp Ala Asp Thr Gln Thr Pro Leu Leu Cys Ser Gln Lys Arg Phe
     305     310     315
Tyr Ser Arg Gly Leu Asn Ser Leu Glu Ser Thr Leu Thr Phe Pro
     320     325     330
Ala Ser Thr Ser Thr Ile
     335

```

<210> 9  
 <211> 686  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc-feature  
 <223> Incyte Clone 1403604

```

<400> 9
Met Gly Pro Arg Ser Arg Glu Arg Arg Ala Gly Ala Val Gln Asn
  1      5      10      15
Thr Asn Asp Ser Ser Ala Leu Ser Lys Arg Ser Leu Ala Ala Arg
      20      25      30
Gly Tyr Val Gln Asp Pro Phe Ala Ala Leu Leu Val Pro Gly Ala
      35      40      45
Ala Arg Arg Ala Pro Leu Ile His Arg Gly Tyr Tyr Val Arg Ala

```

	50		55		60
Arg Ala Val Arg	His Cys Val Arg Ala Phe	Leu Glu Gln Ile Gly			
	65		70		75
Ala Pro Gln Ala	Ala Leu Arg Ala Gln Ile	Leu Ser Leu Gly Ala			
	80		85		90
Gly Phe Asp Ser	Leu Tyr Phe Arg Leu Lys	Thr Ala Gly Arg Leu			
	95		100		105
Ala Arg Ala Ala	Val Trp Glu Val Asp Phe	Pro Asp Val Ala Arg			
	110		115		120
Arg Lys Ala Glu	Arg Ile Gly Glu Thr Pro	Glu Leu Cys Ala Leu			
	125		130		135
Thr Gly Pro Phe	Glu Arg Gly Glu Pro Ala	Ser Ala Leu Cys Phe			
	140		145		150
Glu Ser Ala Asp	Tyr Cys Ile Leu Gly Leu	Asp Leu Arg Gln Leu			
	155		160		165
Gln Arg Val Glu	Glu Ala Leu Gly Ala Ala	Gly Leu Asp Ala Ala			
	170		175		180
Ser Pro Thr Leu	Leu Leu Ala Glu Ala Val	Leu Thr Tyr Leu Glu			
	185		190		195
Pro Glu Ser Ala	Ala Ala Leu Ile Ala Trp	Ala Ala Gln Arg Phe			
	200		205		210
Pro Asn Ala Leu	Phe Val Val Tyr Glu Gln	Met Arg Pro Gln Asp			
	215		220		225
Ala Phe Gly Gln	Phe Met Leu Gln His Phe	Arg Gln Leu Asn Ser			
	230		235		240
Pro Leu His Gly	Leu Glu Arg Phe Pro Asp	Val Glu Ala Gln Arg			
	245		250		255
Arg Arg Phe Leu	Gln Ala Gly Trp Thr Ala	Cys Gly Ala Val Asp			
	260		265		270
Ile Asn Glu Phe	Tyr His Cys Phe Leu Pro	Ala Glu Glu Arg Arg			
	275		280		285
Arg Val Glu Asn	Ile Glu Pro Phe Asp Glu	Phe Glu Glu Trp His			
	290		295		300
Leu Lys Cys Ala	His Tyr Phe Ile Leu Ala	Ala Ser Arg Gly Asp			
	305		310		315
Thr Leu Ser His	Thr Leu Val Phe Pro Ser	Ser Glu Ala Phe Pro			
	320		325		330
Arg Val Asn Pro	Ala Ser Pro Ser Gly Val	Phe Pro Ala Ser Val			
	335		340		345
Val Ser Ser Glu	Gly Gln Val Pro Asn Leu	Lys Arg Tyr Gly His			
	350		355		360
Ala Ser Val Phe	Leu Ser Pro Asp Val Ile	Leu Ser Ala Gly Gly			
	365		370		375
Phe Gly Glu Gln	Glu Gly Arg His Cys Arg	Val Ser Gln Phe His			
	380		385		390
Leu Leu Ser Arg	Asp Cys Asp Ser Glu Trp	Lys Gly Ser Gln Ile			
	395		400		405
Gly Ser Cys Gly	Thr Gly Val Gln Trp Asp	Gly Arg Leu Tyr His			
	410		415		420
Thr Met Thr Arg	Leu Ser Glu Ser Arg Val	Leu Val Leu Gly Gly			
	425		430		435
Arg Leu Ser Pro	Val Ser Pro Ala Leu Gly	Val Leu Gln Leu His			
	440		445		450
Phe Phe Lys Ser	Glu Asp Asn Asn Thr Glu	Asp Leu Lys Val Thr			
	455		460		465
Ile Thr Lys Ala	Gly Arg Lys Asp Asp Ser	Thr Leu Cys Cys Trp			
	470		475		480
Arg His Ser Thr	Thr Glu Val Ser Cys Gln	Asn Gln Glu Tyr Leu			
	485		490		495
Phe Val Tyr Gly	Gly Arg Ser Val Val Glu	Pro Val Leu Ser Asp			
	500		505		510
Trp His Phe Leu	His Val Gly Thr Met Ala	Trp Val Arg Ile Pro			
	515		520		525
Val Glu Gly Glu	Val Pro Glu Ala Arg His	Ser His Ser Ala Cys			



	530		535		540
Thr Trp Gln Gly	Gly Ala Leu Ile Ala	Gly Gly Leu Gly Ala	Ser		
	545		550		555
Glu Glu Pro Leu	Asn Ser Val Leu Phe	Leu Arg Pro Ile Ser	Cys		
	560		565		570
Gly Phe Leu Trp	Glu Ser Val Asp Ile	Gln Pro Pro Ile Thr	Pro		
	575		580		585
Arg Tyr Ser His	Thr Ala His Val Leu	Asn Gly Lys Leu Leu	Leu		
	590		595		600
Val Gly Gly Ile	Trp Ile His Ser Ser	Ser Phe Pro Gly Val	Thr		
	605		610		615
Val Ile Asn Leu	Thr Thr Gly Leu Ser	Ser Glu Tyr Gln Ile	Asp		
	620		625		630
Thr Thr Tyr Val	Pro Trp Pro Leu Met	Leu His Asn His Thr	Ser		
	635		640		645
Ile Leu Leu Pro	Glu Glu Gln Gln Leu	Leu Leu Leu Gly Gly	Gly		
	650		655		660
Gly Asn Cys Phe	Ser Phe Gly Thr Tyr	Phe Asn Pro His Thr	Val		
	665		670		675
Thr Leu Asp Leu	Ser Ser Leu Ser Ala	Gly Gln			
	680		685		

<210> 10  
 <211> 519  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc-feature  
 <223> Incyte Clone 1652936

<400> 10  
 Met Met Ser Lys Asn Asp Gly Glu Ile Arg Phe Gly Asn Pro Ala  
 1 5 10 15  
 Glu Leu His Gly Thr Lys Val Gln Ile Pro Tyr Leu Thr Thr Glu  
 20 25 30  
 Lys Asn Ser Phe Lys Arg Met Asp Asp Glu Asp Lys Gln Glu Thr  
 35 40 45  
 Gln Ser Pro Thr Met Ser Pro Leu Ala Ser Pro Pro Ser Ser Pro  
 50 55 60  
 Pro His Tyr Gln Arg Val Pro Leu Ser His Gly Tyr Ser Lys Leu  
 65 70 75  
 Arg Ser Ser Ala Glu Gln Met His Pro Ala Pro Tyr Glu Ala Arg  
 80 85 90  
 Gln Pro Leu Val Gln Pro Glu Gly Ser Ser Ser Gly Gly Pro Gly  
 95 100 105  
 Thr Lys Pro Leu Arg His Gln Ala Ser Leu Ile Arg Ser Phe Ser  
 110 115 120  
 Val Glu Arg Glu Leu Gln Asp Asn Ser Ser Tyr Pro Asp Glu Pro  
 125 130 135  
 Trp Arg Ile Thr Glu Glu Arg Glu Tyr Tyr Val Asn Gln Phe  
 140 145 150  
 Arg Ser Leu Gln Pro Asp Pro Ser Ser Phe Ile Ser Gly Ser Val  
 155 160 165  
 Ala Lys Asn Phe Phe Thr Lys Ser Lys Leu Ser Ile Pro Glu Leu  
 170 175 180  
 Ser Tyr Ile Trp Glu Leu Ser Asp Ala Asp Cys Asp Gly Ala Leu  
 185 190 195  
 Thr Leu Pro Glu Phe Cys Ala Ala Phe His Leu Ile Val Ala Arg  
 200 205 210  
 Lys Asn Gly Tyr Pro Leu Pro Glu Gly Leu Pro Pro Thr Leu Gln

Pro Glu Tyr Leu	215	Gln Ala Ala Phe Pro	220	Lys Pro Lys Trp Asp	225
Gln Leu Phe Asp	230	Ser Tyr Ser Glu Ser	235	Leu Pro Ala Asn Gln	240
Pro Arg Asp Leu	245	Asn Arg Met Glu Thr	250	Ser Val Lys Asp Met	255
Asp Leu Pro Val	260	Pro Asn Gln Asp Val	265	Thr Ser Asp Asp Lys	270
Ala Leu Lys Ser	275	Thr Ile Asn Glu Ala	280	Leu Pro Lys Asp Val	285
Glu Asp Pro Ala	290	Thr Pro Lys Asp Ser	295	Asn Ser Leu Lys Ala	300
Pro Arg Ser Arg	305	Ser Tyr Ser Ser Thr	310	Ser Ile Glu Glu Ala	315
Lys Arg Gly Glu	320	Asp Pro Pro Thr Pro	325	Pro Pro Arg Pro Gln	330
Thr His Ser Arg	335	Ala Ser Ser Leu Asp	340	Leu Asn Lys Val Phe	345
Pro Ser Val Pro	350	Ala Thr Lys Ser Gly	355	Leu Leu Pro Pro Pro	360
Ala Leu Pro Pro	365	Arg Pro Cys Pro Ser	370	Gln Ser Glu Gln Val	375
Glu Ala Glu Leu	380	Leu Pro Gln Leu Ser	385	Arg Ala Pro Ser Gln	390
Ala Glu Ser Ser	395	Pro Ala Lys Lys Asp	400	Val Leu Tyr Ser Gln	405
Pro Ser Lys Pro	410	Ile Arg Arg Lys Phe	415	Arg Pro Glu Asn Gln	420
Thr Glu Asn Gln	425	Glu Pro Ser Thr Ala	430	Ala Ser Gly Pro Ala	435
Ala Ala Thr Met	440	Lys Pro His Pro Thr	445	Val Gln Lys Gln Ser	450
Lys Gln Lys Lys	455	Ala Ile Gln Thr Ala	460	Ile Arg Lys Asn Lys	465
Ala Asn Ala Val	470	Leu Ala Arg Leu Asn	475	Ser Glu Leu Gln Gln	480
Leu Lys Glu Val	485	His Gln Glu Arg Ile	490	Ala Leu Glu Asn Gln	495
Glu Gln Leu Arg	500	Pro Val Thr Val Leu	505		510
	515				

&lt;210&gt; 11

&lt;211&gt; 334

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc-feature

&lt;223&gt; Incyte Clone 1710702

&lt;400&gt; 11

Met Phe Arg Trp	1	Glu Arg Ser Ile	5	Pro Leu Arg Gly	10	Ser Ala Ala	15
Ala Leu Cys Asn	20	Asn Leu Ser Val	25	Leu Gln Leu Pro	30	Ala Arg Asn	35
Leu Thr Tyr Phe	35	Gly Val Val His	40	Gly Pro Ser Ala	45	Gln Leu Leu	50
Ser Ala Ala Pro	50	Glu Gly Val Pro	55	Leu Ala Gln Arg	60	Gln Leu His	65
Ala Lys Glu Gly		Ala Gly Val Ser		Pro Pro Leu Ile		Thr Gln Val	

	65		70		75
His Trp Cys Val Leu	Pro Phe Arg Val	Leu Leu Val Leu Thr	Ser		
	80		85		90
His Arg Gly Ile Gln	Met Tyr Glu Ser	Asn Gly Tyr Thr Met	Val		
	95		100		105
Tyr Trp His Ala Leu	Asp Ser Gly Asp	Ala Ser Pro Val Gln	Ala		
	110		115		120
Val Phe Ala Arg Gly	Ile Ala Ala Ser	Gly His Phe Ile Cys	Val		
	125		130		135
Gly Thr Trp Ser Gly	Arg Val Leu Val	Phe Asp Ile Pro Ala	Lys		
	140		145		150
Gly Pro Asn Ile Val	Leu Ser Glu Glu	Leu Ala Gly His Gln	Met		
	155		160		165
Pro Ile Thr Asp Ile	Ala Thr Glu Pro	Ala Gln Gly Gln Asp	Cys		
	170		175		180
Val Ala Asp Met Val	Thr Ala Asp Asp	Ser Gly Leu Leu Cys	Val		
	185		190		195
Trp Arg Ser Gly Pro	Glu Phe Thr Leu	Leu Thr Arg Ile Pro	Gly		
	200		205		210
Phe Gly Val Pro Cys	Pro Ser Val Gln	Leu Trp Gln Gly Ile	Ile		
	215		220		225
Ala Ala Gly Tyr Gly	Asn Gly Gln Val	His Leu Tyr Glu Ala	Thr		
	230		235		240
Thr Gly Asn Leu His	Val Gln Ile Asn	Ala His Ala Arg Ala	Ile		
	245		250		255
Cys Ala Leu Asp Leu	Ala Ser Glu Val	Gly Lys Leu Leu Ser	Ala		
	260		265		270
Gly Glu Asp Thr Phe	Val His Ile Trp	Lys Leu Ser Arg Asn	Pro		
	275		280		285
Glu Ser Gly Tyr Ile	Glu Val Glu His	Cys His Gly Glu Cys	Val		
	290		295		300
Ala Asp Thr Gln Leu	Cys Gly Ala Arg	Phe Cys Asp Ser Ser	Gly		
	305		310		315
Asn Ser Phe Ala Val	Thr Gly Tyr Asp	Leu Ala Glu Ile Arg	Arg		
	320		325		330
Phe Ser Ser Val					

<210> 12  
 <211> 569  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc-feature  
 <223> Incyte Clone 3239149

<400> 12  
 Met Asp Pro Ala Glu Ala Val Leu Gln Glu Lys Ala Leu Lys Phe  
 1 5 10 15  
 Met Asn Ser Ser Glu Arg Glu Asp Cys Asn Asn Gly Glu Pro Pro  
 20 25 30  
 Arg Lys Ile Ile Pro Glu Lys Asn Ser Leu Arg Gln Thr Tyr Asn  
 35 40 45  
 Ser Cys Ala Arg Leu Cys Leu Asn Gln Glu Thr Val Cys Leu Ala  
 50 55 60  
 Ser Thr Ala Met Lys Thr Glu Asn Cys Val Ala Lys Thr Lys Leu  
 65 70 75  
 Ala Asn Gly Thr Ser Ser Met Ile Val Pro Lys Gln Arg Lys Leu  
 80 85 90  
 Ser Ala Ser Tyr Glu Lys Glu Lys Glu Leu Cys Val Lys Tyr Phe  
 95 100 105

Glu	Gln	Trp	Ser	Glu	Ser	Asp	Gln	Val	Glu	Phe	Val	Glu	His	Leu
				110					115					120
Ile	Ser	Gln	Met	Cys	His	Tyr	Gln	His	Gly	His	Ile	Asn	Ser	Tyr
				125					130					135
Leu	Lys	Pro	Met	Leu	Gln	Arg	Asp	Phe	Ile	Thr	Ala	Leu	Pro	Ala
				140					145					150
Arg	Gly	Leu	Asp	His	Ile	Ala	Glu	Asn	Ile	Leu	Ser	Tyr	Leu	Asp
				155					160					165
Ala	Lys	Ser	Leu	Cys	Ala	Ala	Glu	Leu	Val	Cys	Lys	Glu	Trp	Tyr
				170					175					180
Arg	Val	Thr	Ser	Asp	Gly	Met	Leu	Trp	Lys	Lys	Leu	Ile	Glu	Arg
				185					190					195
Met	Val	Arg	Thr	Asp	Ser	Leu	Trp	Arg	Gly	Leu	Ala	Glu	Arg	Arg
				200					205					210
Gly	Trp	Gly	Gln	Tyr	Leu	Phe	Lys	Asn	Lys	Pro	Pro	Asp	Gly	Asn
				215					220					225
Ala	Pro	Pro	Asn	Ser	Phe	Tyr	Arg	Ala	Leu	Tyr	Pro	Lys	Ile	Ile
				230					235					240
Gln	Asp	Ile	Glu	Thr	Ile	Glu	Ser	Asn	Trp	Arg	Cys	Gly	Arg	His
				245					250					255
Ser	Leu	Gln	Arg	Ile	His	Cys	Arg	Ser	Glu	Thr	Ser	Lys	Gly	Val
				260					265					270
Tyr	Cys	Leu	Gln	Tyr	Asp	Asp	Gln	Lys	Ile	Val	Ser	Gly	Leu	Arg
				275					280					285
Asp	Asn	Thr	Ile	Lys	Ile	Trp	Asp	Lys	Asn	Thr	Leu	Glu	Cys	Lys
				290					295					300
Arg	Ile	Leu	Thr	Gly	His	Thr	Gly	Ser	Val	Leu	Cys	Leu	Gln	Tyr
				305					310					315
Asp	Glu	Arg	Val	Ile	Ile	Thr	Gly	Ser	Ser	Asp	Ser	Thr	Val	Arg
				320					325					330
Val	Trp	Asp	Val	Asn	Thr	Gly	Glu	Met	Leu	Asn	Thr	Leu	Ile	His
				335					340					345
His	Cys	Glu	Ala	Val	Leu	His	Leu	Arg	Phe	Asn	Asn	Gly	Met	Met
				350					355					360
Val	Thr	Cys	Ser	Lys	Asp	Arg	Ser	Ile	Ala	Val	Trp	Asp	Met	Ala
				365					370					375
Ser	Pro	Thr	Asp	Ile	Thr	Leu	Arg	Arg	Val	Leu	Val	Gly	His	Arg
				380					385					390
Ala	Ala	Val	Asn	Val	Val	Asp	Phe	Asp	Asp	Lys	Tyr	Ile	Val	Ser
				395					400					405
Ala	Ser	Gly	Asp	Arg	Thr	Ile	Lys	Val	Trp	Asn	Thr	Ser	Thr	Cys
				410					415					420
Glu	Phe	Val	Arg	Thr	Leu	Asn	Gly	His	Lys	Arg	Gly	Ile	Ala	Cys
				425					430					435
Leu	Gln	Tyr	Arg	Asp	Arg	Leu	Val	Val	Ser	Gly	Ser	Ser	Asp	Asn
				440					445					450
Thr	Ile	Arg	Leu	Trp	Asp	Ile	Glu	Cys	Gly	Ala	Cys	Leu	Arg	Val
				455					460					465
Leu	Glu	Gly	His	Glu	Glu	Leu	Val	Arg	Cys	Ile	Arg	Phe	Asp	Asn
				470					475					480
Lys	Arg	Ile	Val	Ser	Gly	Ala	Tyr	Asp	Gly	Lys	Ile	Lys	Val	Trp
				485					490					495
Asp	Leu	Val	Ala	Ala	Leu	Asp	Pro	Arg	Ala	Pro	Ala	Gly	Thr	Leu
				500					505					510
Cys	Leu	Arg	Thr	Leu	Val	Glu	His	Ser	Gly	Arg	Val	Phe	Arg	Leu
				515					520					525
Gln	Phe	Asp	Glu	Phe	Gln	Ile	Val	Ser	Ser	Ser	His	Asp	Asp	Thr
				530					535					540
Ile	Leu	Ile	Trp	Asp	Phe	Leu	Asn	Asp	Pro	Ala	Ala	Gln	Ala	Glu
				545					550					555
Pro	Pro	Arg	Ser	Pro	Ser	Arg	Thr	Tyr	Thr	Tyr	Ile	Ser	Arg	
				560					565					

<210> 13  
 <211> 123  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc-feature  
 <223> Incyte Clone 3315936

<400> 13  
 Met Glu Phe Leu Glu Ile Gly Gly Ser Lys Pro Phe Arg Ser Tyr  
                                   5                                  10                                  15  
 Trp Glu Met Tyr Leu Ser Lys Gly Leu Leu Leu Ile Phe Val Val  
                                   20                                  25                                  30  
 Asp Ser Ala Asp His Ser Arg Leu Pro Glu Ala Lys Lys Tyr Leu  
                                   35                                  40                                  45  
 His Gln Leu Ile Ala Ala Asn Pro Val Leu Pro Leu Val Val Phe  
                                   50                                  55                                  60  
 Ala Asn Lys Gln Asp Leu Glu Ala Ala Tyr His Ile Thr Asp Ile  
                                   65                                  70                                  75  
 His Glu Ala Leu Ala Leu Ser Glu Val Gly Asn Asp Arg Lys Met  
                                   80                                  85                                  90  
 Phe Leu Phe Gly Thr Tyr Leu Thr Lys Asn Gly Ser Glu Ile Pro  
                                   95                                  100                                  105  
 Ser Thr Met Gln Asp Ala Lys Asp Leu Ile Ala Gln Leu Ala Ala  
                                   110                                  115                                  120  
 Asp Val Gln

<210> 14  
 <211> 1957  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc-feature  
 <223> Incyte Clone 016108

<400> 14  
 atttttgtca ctttctgtgt gaactaaagt gattcaatgt ctcttttggga ttgcttctgt 60  
 acttcaagaa cacaagttga atcactcaga cctgaaaaac agtctgaaac cagtatccat 120  
 caatacttgg ttgatgagcc aaccctttcc tgggtcacgtc catccactag agccagtga 180  
 gtactatggt ccaccaacgt ttctcactat gagctccaag tagaaatagg aagaggattt 240  
 gacaacttga cttctgtcca tcttgacagg catactccca caggaacact ggtaactata 300  
 aaaattacaa atctggaaaa ctgcaatgaa gaacgcctga aagctttaca gaaagccgtg 360  
 attctatccc actttttccg gcatcccaat attacaactt attggacagt tttcactggt 420  
 ggcagctggc tttgggttat ttctccattt atggcctatg gttcagcaag tcaactcttg 480  
 aggacctatt tccctgaagg aatgagtgaa actttaataa gaaacattct ctttgagacc 540  
 gtgagagggt tgaactatct gcaccaaatt ggctgtattc acaggagtat taaagccagc 600  
 catatectca tttctggtga tggcctagtg accctctctg gcctgtccca tctgcatagt 660  
 ttggttaagc atggacagag gcatagggct gtgtatgatt tcccacagtt cagcacatca 720  
 gtgcagccgt ggttgagtcc agaactactg agacaggatt tacatggggt atatgtgaag 780  
 tcagatatct acagtgttgg gatcacagca tgtgaattag ccagtgggca ggtgcctttc 840  
 caggacatgc atagaactca gatgctgtta cagaaactga aaggctcctc ttatagccca 900  
 ttggatatca gtattttccc tcaatcagaa tccagaatga aaaattccca gtcaggtgta 960  
 gactctggga ttggagaaag tgtgctgttc tccagtgga ctcacacagt aaatagtga 1020  
 cgattacaca caccatcctc aaaaacttct tctcctgcct tctttagctt ggtacagctc 1080  
 tgtttgcaac aagatcctga gaaaaggcca tcagcaagca gtttattgtc ccatgttttc 1140  
 ttcaaacaga tgaagaaga aagccaggat tcaatacttt cactgttgcc tcctgcttat 1200  
 aacaagccat caatatcatt gcctccagtg ttaccttggga ctgagccaga atgtgatttt 1260  
 cctgatgaaa aagactcata ctgggaattc tagggctgcc aaatcatttt atgtcctata 1320

```

tacttgacac tttctccttg ctgctttttc ttctgtattt ctaggtacaa ataccagaat 1380
tatacttgaa aatacagttg gtgcaactgga gaatctatta tttaaaacca ctctgttcaa 1440
aggggacacca gttttagtagt cctctgtttc gcacagagta ctatgacaag gaaacatcag 1500
aattactaat ctagctagtg tcattttattc tggaattttt ttctaagctg tgactaactc 1560
tttttatctc tcaatataat ttttgagcca gtttaattttt ttcagtattt tgctgtccct 1620
tggaatggg cctcagagg acagtgttc caagtacatc ttctcccaga ttctctggcc 1680
tttttaatga gctattgtta aaccaacagg ctagtttatc ttacatcaga cccttttctg 1740
gtagagggaa aatgtttgtg ctttcccttt ttcttctgtt aatacttatg gtaacaccta 1800
actgagctc actcacatta aatgattcac ttgaaatata tacagaaatt gtaatttgct 1860
tttttttaa aaagggggct aaagtaacac ttctctactt atgtaaatta tagatcctaa 1920
attcacgcac ccggtgggag ctcaataaag atttact 1957

```

<210> 15  
 <211> 2545  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc-feature  
 <223> Incyte Clone 640521

```

<400> 15
gagccgagct gggggcgag agcgcgagg gggcgggcg cgcgagacca gtcacccag 60
ctgcagtga gtggtgcgat ctcggtcag tcattgcaac cttcacctcc cggattcaag 120
tgattctcct gcctcagcct cccgagtagc tgggattaca ggtgcccacc accatgccc 180
ggtggtccg ctgcccgatg ggagtgcccc agtggtctgg atgaagctgg cgcagtcacc 240
atgtcatcat gtgtctctag ccagcccagc agcaaccggg ccgccccca ggatgagctg 300
gggggcagg gacagcagc cagcgaaagc cagaagccct gtgagccct gcggggcctc 360
tcattcctga gcattccacct gggcatggag tccttcattg tggtcaccga gtgtgagccg 420
ggctgtgctg tggacctcgg cttggcgcg gaccggcccc tggaggccga tggccaagag 480
gttccccttg actcctccgg gtcccaggcc cgccccacc tctccggtcg caagctgtct 540
ctgcaagagc ggtcccagg tgggctggca gccgttgga gcctggacat gaacggagcg 600
tgcatctgac cgtccctgcc ctactcacc gtcagctccc cgcagtcctc gcctcggctg 660
ccccggcggc cgacagtga gtctcaccac gtctccatca cgggtatgca ggactgtgtg 720
cagctgaatc agtataacct gaagatgaa attggaaagg gctcctatgg tgcgtcaag 780
ttggcctaca atgaaaatga caatacctac tatgcaatga aggtgctgtc caaaaagaag 840
ctgatccggc agcccggtt tccacgtcgc cctccacccc gaggcacccg gccagctcct 900
ggaggctgca tccagcccag gggccccatt gagcaggtgt accaggaaat tgccatcctc 960
aagaagctgg accaccccaa tgtgtgaaag ctggtggagg tcctggatga ccccaatgag 1020
gaccatctgt acatggtgtt cgaactggtc aaccaagggc ccgtgatgga agtgcccacc 1080
ctcaaacccac tctctgaaga ccaggcccgt ttctacttcc aggatctgat caaaggcatc 1140
gagtacttac actaccagaa gatcatccac cgtgacatca aaccttccaa cctcctggtc 1200
ggagaagatg ggcacatcaa gatcgtgac tttggtgtga gcaatgaatt caagggcagt 1260
gacgcgctcc tctccaacac cgtgggcacg cccgccttca tggcacccga gtcgctctct 1320
gagacccgca agatcttctc tgggaaggcc ttggatgttt gggctatggg tgtgacacta 1380
tactgctttg tctttggcca gtgcccattc atggacgagc ggatcatgtg tttacacagt 1440
aagatcaaga gtcaggccct ggaatttcca gaccagccc acatagctga ggacttgaag 1500
gacctgatca cccgtatgct ggacaagaac cccagatcga ggatcgtggt gccggaaatc 1560
aagctgcacc cctgggtcac gaggcaggg gcggagccgt tggcgtcgga ggatgagaac 1620
tgacagctgg tcgaagtga tgaagaggag gtcgagaact cagtcaaaac cattcccagc 1680
ttggcaaccg tgatcctggt gaagaccatg atacgtaaac gtccttttgg gaaccattc 1740
gagggcagcc ggcgggagga acgctcactg tcagcgcctg gaaacttgc caggaagcaa 1800
ggcagcgaag acaacctcca gggcaccgac ccgcccccg tgggggagga ggaagtgtc 1860
ttgtgagagg cagtccctgc gtgaaagt gctgggcccc cgccccggc tccccgcac 1920
gcatgcatcc actgcggcgg gaggagccca tggagccga gtagctgcct ggatcgtctg 1980
acctgcgat cgcccgcgct gcctctgtgg gggctgtcgc accgcgttc catagcagca 2040
tgtcctacgg aaacccagca cgtgtgtaga gcctcgatcg tcatctctgg ttatttgttt 2100
tttcccttgt tgttttaaag gggacaaaa aaaaaaaaa aaggacttga ctccatgacg 2160
tcgacctggt ccgctggctg gctggacagg cgggtgtgag gatttgacga cccaaaccca 2220
cgtgcatttt gggacaattg ctttttaaaa cgtttttatg ccaaaaatcc ttcatgtga 2280
ttttcagaac cagctcagat ataccaagt actgtgtgtg gggtttgaca actgtggaaa 2340
ggcagacaga aaactccggc ggtctgagc catggagggt gttgtgcat ttgagaggga 2400
gtagggggct agatgtggct cctagtga accggaaacc atggcacct ccagagccgt 2460

```

ggctctcaagg agtcagagca gggctggccc tcagtagctg caggagcctt tgatggcaac 2520  
ttattttgtt aagaagggtt ttttt 2545

<210> 16  
<211> 3034  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc-feature  
<223> Incyte Clone 1250171

<400> 16  
tcctgagtct cgaggaggcc gcgggagccc gccggcggtg gcgcggcgga gacccggctg 60  
gtataacaag aggattgcct gatccagcca agatgcagag cacttcta atcatctgtggc 120  
ttttatctga tatttttagc caaggagcta ctgcaaacgt ctttcgtgga agacataaga 180  
aaactgggtga tttatttgct atcaaaagtat ttaataacat aagcttcctt cgtccagtgg 240  
atgttcaa at gagagaattt gaagtgttga aaaaactcaa tcacaaaaat attgtcaa at 300  
tatttgctat tgaagaggag acaacaacaa gacataaagt acttattatg gaattttgtc 360  
catgtgggag tttatacact gttttagaag aaccttctaa tgcctatgga ctaccaga at 420  
ctgaattctt aattgttttg cgagatgttg tgggtggaat gaatcatcta cgagagaatg 480  
gtatagtgc cctgatatc aagccaggaa atatcatgct tgttataggg gaagatggac 540  
agtctgtgta caaactcaca gattttgggt cagctagaga attagaagat gatgagcagt 600  
ttgtttctct gtatggcaca gaagaatatt tgcacctga tatgtatgag agagcagtgc 660  
taagaaaaga tcatcagaag aaatatggag caacagttag tctttggagc attggggtaa 720  
cattttacca tgcagctact ggatcactgc catttagacc ctttgaaggg cctcgtagga 780  
ataaagaagt gatgtataaa ataattacag gaaagccttc tgggtcaata tctggagtag 840  
agaaagcaga aaatggacca attgactgga gtggagacat gcctgtttct tgcagtcttt 900  
ctcggggtct tcaggttcta cttacccttg tcttgcaaa catccttgaa gcagatcagg 960  
aaaagtgttg gggttttgac cagttttttg cagaaactag tgatatactt caccgaatgg 1020  
taattcatgt tttttcgcta caacaaatga cagctcataa gatttatata catagctata 1080  
atactgctac tatatttcat gaactgggtat ataaacaaac caaaattatt tcttcaaatc 1140  
aagaacttat ctacgaagg cgagccttag tcttagaacc tgggaaggctg gcacaacatt 1200  
tccctaaaac tactgaggaa aaccctatat ttgtagtaag ccgggaacct ctgaatacca 1260  
taggattaat atatgaaaaa atttcctctc ctaaaagtaca tccacgttat gatttagacg 1320  
gggagtctag catggctaag gcaataacag gggttgtgtg ttatgcctgc agaattgcca 1380  
gtaccttact gctttatcag gaattaatgc gaaaggggat acgatggctg attgaattaa 1440  
ttaaagatga ttacaatgaa actgttcaca aaaagacaga agttgtgatc acattggatt 1500  
tctgtatcag aaacattgaa aaaactgtga aagtatatga aaagtgtatg aagatcaacc 1560  
tgggaagcgc agagttaggt gaaatttcag acatacacac caaattgttg agactttcca 1620  
gttctcagg gaccaatgaa accagtcttc aggatatcga cagcagatta tctccagggtg 1680  
gatcactggc agacgcattg gcacatcaag aaggcactca tccgaaagac agaaatgtag 1740  
aaaaactaca agtcctgtta aattgcatga cagagattta ctatcagttc aaaaaagaca 1800  
aagcagaacg tagattagct tataatgaag aacaaatcca caaatttgat aagcaaaaac 1860  
tgtattacca tgccacaaaa gctatgacgc actttacaga tgaatgtgtt aaaaagtatg 1920  
aggcattttt gaataagtca gaagaatgga taagaaagat gcttcatctt aggaacaggt 1980  
tattatcgct gactaatcag tgttttgata ttgaagaaga agtatcaaaa tatcaagaat 2040  
ataactaatga gttacaagaa actctgcctc agaaaatgtt tacagcttcc agtggaaatc 2100  
aacataacct gacccaatt tatccaagtt ctaacacatt agtagaaatg actcttggtg 2160  
tgaagaaatt aaaggaagag atggaagggtg tggttaaaga acttgctgaa aataaccaca 2220  
ttttagaaag gtttggtctt ttaaccatgg atggtggcct tcgcaacgtt gactgtcttt 2280  
agctttctaa tagaagttta agaaaagttt ccgtttgcac aagaaaataa cgcttgggca 2340  
ttaaatgaat gcctttatag atagtcactt gtttctacaa ttcagtattt gatgtggtcg 2400  
tgtaaatatg tacaatatgt taaatacata aaaaatatac aaatttttgg ctgctgtgaa 2460  
gatgtaattt tatcttttaa catttataat tatatgagga aatttgacct cagtgtatcac 2520  
gagaagaaag ccatgaccga ccaatatgtt gacatactga tcctctactc tgagtggggc 2580  
taataaagt attttctctg accgcctact ggaatatatt ttaagtggaa ccaaaatagg 2640  
catccttaca aatcaggaag actgacttga cacgtttgta aatggtagaa cggtgggtac 2700  
tgtgagtggg gagcagaacc gcaccactgt tatactggga taacaatttt tttgagaagg 2760  
ataaagtggc attattttat tttaacaagg gccagatccc cagttatcct tgtatccatg 2820  
taatttcaga tgaattatta agcaaacatt ttaagtga ttcatatta aaaactattc 2880  
atttttttcc tttggccata aatgtgtaat tgtcattaaa attctaaggt catttcaact 2940  
gttttaagct gtatatttct ttaattctgc ttactatttc atggaaaaaa ataaatttct 3000

caatttttaaa aaattttttt ataaaaaaaaa aaaa

3034

<210> 17  
<211> 1337  
<212> DNA  
<213> Homo sapiens  
  
<220>  
<221> misc-feature  
<223> Incyte Clone 1911587

<400> 17  
gaaagctgtg ggaccatcct ggcaaccccg gtgtttggct gggttctagc gtaccgtctg 60  
tgtggccggt gggggacctg cggtcggagt gggagggcca gtctgcaccc aagaggtgga 120  
agaggacggg ctttaggctg gaagcgcctt agaggagcca ttttccagg tggggcccca 180  
ggcagaggct ccgacaggga gcctggccat agtcgcgcac caggggaggt ggagcgcgtc 240  
ccagaccgga gccccgacc tcagccaaac ccattccttc tgccttgga ggccagagg 300  
gactctgagc atcggaagc aggatgcctg gtttgctttt atgtgaacca acagagcttt 360  
acaacatcct gaatcaggcc acaaaactct ccagattaac agaccccaac tatctctgtt 420  
tattggatgt ccgttccaaa tgggagtatg acgaaagcca tgtgatcact gcccttcgag 480  
tgaagaagaa aaataatgaa tatcttctcc cggagtctgt ggacctggag tgtgtgaagt 540  
actgcgtggt gtatgataac aacagcagca ccctggagat actcttaaaa gatgatgatg 600  
atgattcaga ctctgatggt gatggcaaag atcttgtgcc tcaagcagcc attgagtatg 660  
gcaggatcct gaccgcctc acccaaccac ccgtctacat cctgaaaggg ggctatgagc 720  
gcttctcagg cacgtaccac tttctccgga ccagaagat catctggatg cctcaggaac 780  
tggatgcatt tcagccatac ccattgaaa tcgtgccagg gaaggtcttc gttggcaatt 840  
tcagtcaagc ctgtgacccc aagattcaga aggacttgaa aatcaaagcc catgtcaatg 900  
tctccatgga tcaggggcc tttttgcag gcgatgctga caggcttctg cacatccgga 960  
tagaagattc ccgggaagcc cagattcttc ccttcttacg ccacatgtgt cacttcattg 1020  
aaattcacca tcacctggc tctgtcattc tgatcttttc caccagggt atcagccgca 1080  
gttgtgccgc catcatagcc tacctcatgc atagtaacga gcagacctg cagaggtcct 1140  
gggcctatgt caagaagtgc aaaaacaaca tgtgtccaaa tcggggaatg gtgagccagc 1200  
tgctggaatg ggagaagact atccttgag attccatcac aaacatcatg gatccgctct 1260  
actgatcttc tccgaggccc accgaagggt actgaagagc ctcacctggg ggcattttgt 1320  
gggtggaggg ccagagt 1337

<210> 18  
<211> 1639  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc-feature  
<223> Incyte Clone 2079081

<400> 18  
gacaaaagcc agacacattt caacatgagg gaccactga cagattgtcc gtataataaa 60  
gtatacaaga acctaaagga gttttctcaa aatggagaga atttctgcaa acaggtcaca 120  
tctgttcttc agcaaagggc aaacctggaa attagctatg ccaaaggact tcagaaactg 180  
gcaagcaagc tgagcaaagc attacagaac acgagaaaaa gttgtgtag cagtgcctgg 240  
gcctgggcct cagaggggaat gaaatccaca gcggacctgc atcaaaaact tggcaaagca 300  
attgaattgg aagcaataaa accgacttat caagtcctaa atgtacaaga gaagaagaga 360  
aaatcacttg acaatgaagt tgaaaagaca gcaaactctg tcattagcaa ctggaatcag 420  
caaattaagg ccaagaagaa attaatggtt agtaccaga aacatgaagc acttttccag 480  
cttgtagaaa gctccaagca atctatgact gagaaggaga agcggagct cctcaataaa 540  
ctgacaaaat caactgaaa gttggaaaag gaagatgaaa attactacca aaaaaacatg 600  
gcgggttatt ctaccagact gaaatgggaa aacacactag agaactgcta ccagagcatt 660  
ctggagctgg agaaggaaa aattcaactt ttatgcaata acttaacca gtacagccaa 720  
catatttctc tttttggcca aacctgacc acatgccaca cgcagattca ctgtgccatc 780  
agcaagattg acattgaaaa agatatccag gctgtaatgg aagaaactgc aattttatct 840  
acagaaaaa aatctgagtt cctgttaacg gattactttg aagaagatcc taacagtgc 900  
atggataaag agagacgaaa gtctttacta aaacaaaaat tattgagact gcagagagac 960



```

attgaaaaag cctcaaaaaga caaggaaggc ctggaacgaa tgcttaaaac gtactccagc 1020
acctcctcct tctctgatgc aaagagccag aaagacacag cagcgtaaat ggatgagaac 1080
aatttgaaac tagacctttt ggaagcgaac tctacaaaac tgtcatcaat gtagcagaa 1140
cttgagcaaa gacctcaacc cagccatcct tgtagtaatt ccattctcag gtggaggaa 1200
aaggagcata ctcatagcta tgtgaaaata tctcgccctt ttttaatgaa gagattagag 1260
aatattgtga gcaaggcatc ttctggtggg cagagcaatc cagggtcttc aactccagcc 1320
cctggtgcag cccagctcag cagcagactt tgcaaggcct tgtattcttt tcaagccagg 1380
caagatgatg agttgaattt ggaaggggt gacattgtga ttatacacga gaaaaaagaa 1440
gaaggatggt ggtttggatc tttgaatggg aaaaaaggcc attttcctgc cgcttatgtg 1500
gaggagttag cttcaaatgc tggcaacaca gctacaaagg cataaaacaa gactctgaac 1560
atactacctt cacactcggg aatcaacaat acagtgtggt tcaataaaga ataaagtgtc 1620
cttaccttta aaaaaaaaaa

```

```

<210> 19
<211> 1504
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc-feature
<223> Incyte Clone 2472655

```

```

<400> 19
cgaaatcgta ggacttccga aagcagcggg ggcgtttgct tctactgctg gaagtgtgag 60
tgcgcaaga tgcgaaagggt ggttttgatc accggggcta gcagtggcat tggcctggcc 120
ctctgcaagc ggctgctggc ggaagatgat gagcttcac tgtgtttggc gtgcaggaa 180
atgagcaagg cagaagctgt ctgtgctgct ctgctggcct ctacccccac tgtgaggtc 240
accattgtcc aggtggatgt cagcaacctg cagtcgggtc tccgggcctc caaggaaact 300
aagcaaagggt ttcagagatt agactgtata tatctaaatg ctgggatcat gcctaatacca 360
caactaaata tcaaaagcact tttctttggc ctcttttcaa gaaaagtgat tcatatgttc 420
tccacagctg aaggcctgct ,accagggt gataagatca ctgctgatgg acttcaggag 480
gtgtttgaga ccaatgtctt tggccatttt atcctgattc gggaactgga gcctctcctc 540
tgtcacagtg acaatccatc tcagctcatc tggacatcat ctgcagtgcc aaggaaatct 600
aatttcagcc tcgaggactt ccagcacagc aaaggcaagg aacctacag ctcttccaaa 660
tatgccactg accttttgag tgtggctttg aacaggaact tcaaccagca gggctctctat 720
tccaatgtgg cctgtccagg tacagcattg accaatttga catatggaat tctgcctccg 780
tttatatgga cgctgttgat gccggcaata ttgctacttc gcttttttgc aaatgcattc 840
actttgacac catataatgg aacagaagct ctggtatggc ttttccacca aaagcctgaa 900
tctctcaatc ctctgatcaa atatctgagt gccaccactg gctttggaag aaattacatt 960
atgaccagaa agatggacct agatgaagac actgctgaaa aattttatca aaagtactg 1020
gaactggaaa agcacattag ggtcactatt caaaaaacag ataatcaggc caggctcagt 1080
ggctcatgcc tataattcca gcactttggg aggccaaggc agaaggatca cttgagacca 1140
ggagttaag accagcctga gaaacatagt gagcccttgt ctctacaaaa agaaataaaa 1200
ataatagctg ggtgtggtgg catgctgcatg tagtcccagc tactcagaag gatgagggtg 1260
gaggatctct tgaggctggg aggcagaggt tgcagtgagc tgagattgtg ccactgcact 1320
ccagcctggg tgacagcgag accctgtctc aaaatatgta tatatttaat atatatataa 1380
aaccagagct gacaatgaca ctctggaaca ttgcatacct tctgtacatt ctgggttaca 1440
tggatttcta ctgagttgga taatatgcat ttgtaataaa ctatgaacta tgaaaaaaa 1500
aaaa
1504

```

```

<210> 20
<211> 3096
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc-feature
<223> Incyte Clone 2948818

```

```

<400> 20
gggtgttctt ataacttaag ttcagttttt tctttcctgt gaggaagagg cagtttttta 60
aatgaagcca tctctgggga aatcgtattg attgtttag ctataacag aatttttaaa 120

```

```

gtcttttagta tgttgaactg gaaatatag agatgcgttt gagatctact gtgagttgca 180
tcataaatatc aaaggactga agttataaaa gagaaaagag aagtttgctg ctaaaatgaa 240
tctgagcaat atggaatatt ttgtgccaca cacaaaaagg tactgaggat ttacccccca 300
aaaaaaattg tcaatgagaa ataaagctaa ctgatatcaa aaagcagagc ctgctctact 360
ggccatcatg cgtaaaaggg tgctgaagga ccagagatt gccgatctat cctacaaaga 420
tgatcctgag gaacttttta ttggtttgca tgaaattggg catggaagt ttggagcagt 480
ttattttgct acaaagtctc acaccagtga ggtggtggca attaagaaga tgcctatag 540
tgggaagcag acccatgaga aatggcaaga tattcttaag gaagttaa ttttacgaca 600
attgaagcat cctaatacta ttgagtacaa aggctgttac ttgaaagaac aactgcttg 660
gttggtgatg gaatttgct taggctcagc ctctgattta ttagaagttc ataaaaaacc 720
acttcaggaa gtggagatcg ctgccattac tcatggagcc ttgcatggac tagcctacct 780
acattctcat gcattgattc atagggatat taaagcagga aatattcttc taacagagcc 840
aggtcaggta aaactagctg attttggatc tgcttcaatg gcttctcctg ccaactcctt 900
cgtagggcaca ccttactgga ttggtccaga ggtgatctta gctatggatg aaggacagta 960
tgatgggaaa gttgatattt ggtcacttgg catcacttgt attgaattgg cggaacggaa 1020
gccgcccctt ttcaacatga atgcaatgag tgccttatat cacattgccc agaagtactc 1080
cccaacgtta cagtctaattg aatggacaga ctcctttagg agattttgtt attactgctt 1140
gcagaaaaata cctcaggaaa ggccaacatc agcagaacta ttaaggcatg actttgttctg 1200
acgagaccgg ccactacgtg tcctcattga cctcatcacg aggacaaaag atgcagtctg 1260
tgagctagat aacctacagt accgaaaaat gaaaaaaata cttttccaag agacacggaa 1320
tggacccttg aatgagtcac aggaggtatg ggaagacagt gaacatggaa ccagcctgaa 1380
caggggaaatg gacagcctgg gcagcaacca ttccattcca agcatgtccg tgagcacagg 1440
cagccagagc agcagtgtga acagcatgca ggaagtcatg gacgagagca gttccgaact 1500
tgtcatgatg cacgatgacg aaagcacaat caattccagc tcctccgctg tgcataagaa 1560
agatcatgta ttcataaggg atgaggcggg ccacggcgat cccaggcctg agccgcgggc 1620
taccacatca gttcagagcc aggccctcca ctaccgggaa agagagcgct ttgccacgat 1680
caaatacgca tctttggtta cacgacagat ccatgagcat gaggcaggaga acgagttgctg 1740
ggaacagatg tcaggttata agcggatgctg gcgccagcac cagaagcagc tgatcgccct 1800
ggagaacaag ctgaaggctg agatggacga gcaccgcctc aagctacaga aggaggtgga 1860
gacgcattgc aacaactcgt ccactcagct ggagaagctg gccaagaagc aagtggctat 1920
catagaaaaa gaggcaaaag tagctgcagc agatgagaag aagttccagc aacagatctt 1980
ggcccgagcag aagaaaatt tgacaacttt cttagaaaag cagaagaagc agtataagat 2040
ttgtaaggaa aaaataaaa aggaaatgaa tgaggaccat agcacacca agaaagagaa 2100
gcaagagcgg agtcctaaac ataaagagaa cttgcagcac acacaggctg aagaggaagc 2160
ccacctttct actcaacaga gactgtacta cgacaaaaat tgcgttttct tcaagcgaa 2220
aataatgatc aagcggcacg aggtggagca gcagaacatt cgggaggaac taaataaaaa 2280
gaggacccag aaggagatgg agcatgccat gctaattccg cagcagcagt ccaccgaga 2340
gctagagtag agcagctgc acacgttaca gaagctacgc atggatctga tccgtttaca 2400
gcaccagacg gaactggaaa accagctgga gtacaataag aggcgagaaa gagaactgca 2460
cagaaagcat gtcattgaaac ttcggcaaca gccaaaaaac ttaaaaggcca tggaaatgca 2520
aattaaaaaa cagtttcagg aacttgcaa agtacagacc aaacagtata aagcactcaa 2580
gaatcaccag ttggaagtta ctccaagaa tgagcacaaa acaatcttaa agacactgaa 2640
agatgagcag acaagaaaac ttgccatttt ggcagagcag tatgaacaga gtataaatga 2700
aatgatggcc tctcaagcgt tacggctaga tgaggctcaa gaagcagaat gccaggcctt 2760
gaggctacag ctccagcagg aaatggagct gctcaacgcc taccagagca aaatcaagat 2820
gcaaacagag gcacaacatg aacgtgagct ccagaagcta gacgagagag tgtctctgctg 2880
cagagcacac cttgagcaga agattgaaga ggagctggct gcccttcaga aggaacgcag 2940
cgagagaata aagaacctat tggaaaggca agagcgagag attgaaactt ttgacatgga 3000
gagcctcaga atgggatttg ggaatttggt tacattagat tttcctaagg aggactacag 3060
atgagattaa attttttgcc atttacaaaa aaaaaa 3096

```

<210> 21  
 <211> 1527  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc-feature  
 <223> Incyte Clone 054191

<400> 21  
 ctccgcttga ggagaagcgc caagtgcgca tggggacgct atagcaattc gtttgctgtc 60  
 cttcctctcc ttcgaagatg acaaggccta ccatcgcttc ttctgctctt tggggcggtca 120

```

ggcagttggt tgggaccgc tccaaccctc ggttcttcct gcaatacagt ggatacaatt 180
tgtcatggct actctgagtg ttatagggtc aagttcactt attgcctatg ctgtattcca 240
taatatacag aaatctccag agataagacc acttttttat ctgagcttct gtgacctgct 300
cctgggactt tgctggctca cggagacact tctctatgga gcttcagtag caaataagga 360
catcatctgc tataacctac aagcagttgg acagatattc tacatttcct cttttctcta 420
caccgtcaat tacatctggt atttgtacac agagctgagg atgaaacaca cccagagtgg 480
acagagcaca tctccactgg tgatagatta tacttgctga gttgggtcaaa tggcctttgt 540
tttctcaagc ctgatacctc tgctattgat gacacctgta ttctgtctgg gaaatactag 600
tgaatgtttc caaaacttca gtcagagcca caagtgtatc ttgatgact caccaccatc 660
agccatggct gaacttccac cttctgccaa cacatctgtc tgtagcacac tttattttta 720
tggatcggc attttctgg gcagctttgt actcagcctc cttaccatta tggcttact 780
tatccgagcc cagacattgt ataagaagt tgtgaagtca actggctttc tggggagtga 840
acagtgggca gtgattcaca ttgtggacca acgggtgcgc ttctaccag tggccttctt 900
ttgctgctgg gggccagctg tcattcta atgcataaag ctgactaagc cacaggacac 960
caagcttcac atggcccttt atgttctcca ggctctaagc gcaacatctc agggcttact 1020
caactgtgga gtatatggct ggacgcagca caaattccac caactaaagc aggaggctcg 1080
gcgtgatgca gataccaga caccattatt atgctcacag aagagattct atagcagggg 1140
cttaaatcca ctggaatcca cctgactttt tctgccagt acttctacca ttttttgaaa 1200
ctacaatact ggaacatcca ggaactggag ttattctacg ctaattggatt ggaaagaatg 1260
ttgggaaagg acatcttaaa tcttttctaa ctatgcccta aactgcagaa ctcaaaggaa 1320
atatagtgcc attgttagta gtcattctag atgaattggg agtatctctc cagttattcc 1380
cagattcact agtgatcctt aaagtctcta ttcagggaga ggaagacact ttccatctca 1440
gagatagact cgtgttacct tgatggatat tggatttgtc taagtctctt ctagaaaaaa 1500
taaattctag attattaaaa aaaaaaa 1527

```

&lt;210&gt; 22

&lt;211&gt; 2948

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc-feature

&lt;223&gt; Incyte Clone 1403604

&lt;400&gt; 22

```

aaagaaaggt cagccgcaag cgaacttagc actggctaca ccctcctcaa ttctggttgg 60
cgagatgcgc tcttcccgga agtgacgcac aagtgcgcgc ggaaggggaa gtccaggagc 120
atgggtggtt tttttccccc taccgaggtc cgtgaggtgt gtgctaacca aggggcggt 180
cacaaccgtg acagactgcc attcctgagt ctcttctggc catgggcccc cggagccgtg 240
agcgtcgggc aggcgcggta cagaacacca acgacagcag cgcctcagc aagcgttccc 300
ttggccgcgc cgggtacgtg caggaccctt ttgccggtt gctggttccg ggccgcgccg 360
ggccgcgacc gctcattcac cgaggctact acgtccgcgc acgcgcctg aggcactgcg 420
tgcgcgcttt ttggagcag attggcgcgc cccaggccgc gcttcgcgcg cagatcttgt 480
ctctcggcgc tggcttcgac tcgctctatt ttgccttaa aaccgcgggc cgcttgccc 540
gggctgcagt ctgggaggtg gattttccgg acgtggcgcg gcgcaaagca gaaaggattg 600
gagagacgcc agagctgtgc gcgttaaccg ggcttttcga gaggggggag cccgcgtccg 660
cgctgtgctt tgagagcgca gactactgca tcctgggtct ggacttgccg cagctccagc 720
gagtggagga ggccctgggc gccgcggggc tcgacgcagc ctacccact ctgctcctgg 780
ccgagggcgt gctgacctac ctcgagccgg agagtgcgc ggccctcatc gcctgggcag 840
cccagcgttt tccaatgcc ctttctgtg tctatgagca gatgaggcct caagacgcct 900
ttggccagtt catgctgcaa ctttttcggc agctaaactc cccctgcat ggctggagc 960
gttttctga cgtggaggcg cagcggcgcc gcttcttca agctggctgg accgcctgcg 1020
gtgccgtgga cataaatgaa ttctatcact gctttcttcc cgcagaagaa cggcggcggg 1080
tggaaaatat tgaacctttt gacgaatttg aggagtggca tctgaagtgc gccattatt 1140
tcattctggc agcttctagg ggagacaccc tctccacac cctagtgtt ccatcctcag 1200
aggcatttcc tcgcgtaaat cctgcttcgc cttcagggtt attcctgcc agcgtagtca 1260
gtagcgaggg ccaggccca aacctgaaga gatatggcca cgcctctgtc ttcttgagcc 1320
cagacgttat tctcagtga ggaggtttg gagagcagga ggggcggcac tgccgagtga 1380
gccagtttca cttgctctca agagattgtg actctgaatg gaaaggcagc caaataggca 1440
gttggtggac tggagttcag tgggatggac gcctttatca caccatgaca agactctcag 1500
agagtcgggt tctggttctg ggagggagac tgtccccagt aagtcagacc ttgggggttc 1560
tccagcttca tttttttaag agtgaggata ataactga ggacgtgaaa gtgacaataa 1620
caaaggctgg ccgaaaggat gattccactt tgtgtgtgtg gcggcattca acaacagaag 1680

```

```

tgtcctgtca gaatcaggaa tatttgtttg tgtatggggg tcgaagcgtg gtggaacctg 1740
tactaagtga ctggcatttc ctccatgtag ggacaatggc ttgggtcagg atcccagtg 1800
agggagaagt acctgaagcc cggcattctc acagtgcctg cacttgccaa gggggagccc 1860
ttattgctgg aggtctcggg gcttctgagg agccattgaa ctctgtgctc tttctgagac 1920
caatctcttg tggattcctc tgggagtcag tagacatcca gcctcccatt accccaaggt 1980
actcccacac agctcatgtg ctcaatggaa agctgttact gggtggaggg atctggattc 2040
attcctcctc atttccctga gtgactgtga tcaatttgac tacaggattg agctctgagt 2100
atcagattga cacaacatat gtgccatggc cattaatgtt acacaacat actagtatcc 2160
ttcttcctga agagcaacag ctccctgctc ttggagggtg tgggaactgc ttttcctttg 2220
gtacctactt caaccctcat acagtcacat tagaccttcc ttccttaagt gctgggcagt 2280
aaggactgga ctaatatcca ggaccacta aagtagacaa taaagttttc cacaaatagg 2340
atgacctctt agctatagat actgccactc ctccctttcc catccttttt tcccttagc 2400
actattcagt gcaaaaagtg aaaaagggtg gtaaaaatagg taaaatacct agaaacaatc 2460
actacagaaa acagctgaag acagtggcca tgcagtcoga gaggagtagt ggtctgcctc 2520
taattttcta atctaagttc gtttattgag ttacagtggg ctttagtaaa gtaaaacaat 2580
ttcccaatcc caggccttgt gatttgagat ggtaccttag aaaaagttac acgcagttcc 2640
tggttggaat atatttgaga tggtagctta gaaaaagttt cacgcagatc cttggttgaa 2700
tatagttgag ggagcgtagt attgacaatt cttcatgtag gaaacctgaa atgaacacag 2760
tcacagtttg attaaaacat tgtcctgttt gttgcaacag aaaactcgga tagttttaac 2820
aacaggaaac acttgtagga cttcctttac caacatactt tttaaatgtt ttgctattgg 2880
ttccatattt atttagattt ataagtgtca ataaagcaaa cttttgatgc ctcaaaaaaa 2940
aaaaaaa

```

&lt;210&gt; 23

&lt;211&gt; 1808

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc-feature

&lt;223&gt; Incyte Clone 1652936

&lt;400&gt; 23

```

gagagtatta aatgtgaatt gcctctgcct cgctttatga tgtcaaagaa tgatggtag 60
atacagattg ggaacccagc tgagctgcat ggaactaagg ttcagattcc atatttaact 120
acagaaaaaa attccttcaa aagaatggac gatgaggata aacaggaaac acagtctccc 180
acgatgtcac ccctcgccctc ccctccttct tccccgctc attaccagag ggtgcccttg 240
agccatggct acagcaaaact gcggagcagc gcagaacaga tgcattccagc accttatgaa 300
gctaggcagc cccttggtcca gcccgaggga tcctcatcag ggggcccagg aaccaagccc 360
cttcggcatc aggccttccct tatccgggtc ttttcagtgg agagggaaact acaggataac 420
agcagttacc ccgacgaacc ctggaggata acagaagaac agcgcgagta ctatgtcaat 480
cagttccgat cccttcagcc agaccaagc tctttcattt caggttctgt ggccaagaac 540
ttcttcacca aatcaaagct ttccattcca gaactctcct atatattgga gcttagtgat 600
gctgactgtg atggagccct gaccctgcct gagtctctgt ctgctgttca tctcattgtg 660
gctcgggaaga acggctaccc attgcctgag ggcctccctc caactctgca gccagaatac 720
ctgcaggcag cttttcctaa gcccaaatgg gactgtcaat tatttgattc ttattctgag 780
tcaactgccg caaatcaaca acctcgtgac ttgaatcgga tggagacatc tgttaaagac 840
atggctgacc ttctgtccc taaccaggat gtaactagt atgacaaaac agctttgaaa 900
agtactatca atgaagcctt accaaaggac gtgtctgagg atccagcaac tcccaaggat 960
tccaacagtc tcaaagcaag accaagatcc agatcttact ctacacctc catagaagag 1020
gccatgaaaa ggggagagga ccctcccacc ccgccacctc ggccacagaa aaccatttcc 1080
agagcctcct ccttggtact gaataaagtc ttccagccca gtgtgccagc taccagtgca 1140
ggattgttac ccccaccacc tgcgtccctt ccaagacctt gtccatcaca gtctgaacaa 1200
gtgtcggagg ccgagttact cccacagctg agcagagccc catcccaggc tgcagaaagt 1260
agtccagcaa agaaggatgt actgtattct cagccaccat caaagcccat tcgtaggaaa 1320
ttcagaccag aaaaaccaagc tacagaaaac caagagcctt ccactgctgc aagtgggcca 1380
gcttctgcgg caacctgaa accgcatcca acagtccaaa agcagctctc caaacagaag 1440
aaggccattc aaactgctat ccgcaaaaat aaagaggcaa acgcagtgtt ggctcggctg 1500
aacagtgagc tccagcagca gctcaaggag gttcatcaag aacgaattgc attggaacaa 1560
caattggaac aacttcgtcc ggtcactgtg ttgtgacccc cccatgggtt aagtgcagct 1620
gggtgacctt gctcgccaag atctttcttt tgaatgtttt gaacccaact acttgtcata 1680
gatgtttgac tgtgtcaaaa gctgtgagca gcaaaaatata atccatatga ctttttctct 1740
tgtatagact taaaaaaa aaaaatagatc ttaattaagg cggctcgcaag cttattccct 1800

```

ttagtgag

1808

<210> 24  
 <211> 1148  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> misc-feature  
 <223> Incyte Clone 1710702

<400> 24  
 tgcgtacgtg cgtcgtctct atggtggcgg cggatttga gggaccctac gaaccaggag 60  
 tcaggcgagc cgtatctggg ctgcaggatg ttccgctggg agcgctccat tccpctgcga 120  
 ggctcggccg ccgccctgtg caacaacctc agtgtgtgc agctgccggc tcgcaacctc 180  
 acgtattttg gcgtggttca tggaccaagc gccagcttc tcagcgctgc tcctgagggt 240  
 gtgcccttgg ccagcgcca gctccacgct aaggagggtg ctggagttag tccccactt 300  
 atcactcagg tccactggtg tgcctcccc ttccgagtgc tgcgtgtact cacctcacat 360  
 cgaggaatac agatgtacga gtccaatggc tacaccatgg tctactggca tgcactggac 420  
 tctggagatg cctccccagt acaggctgtg ttgcccggg gaattgctgc cagtggccac 480  
 ttcatctgtg tgggaacgtg gtcaggccgg gtgctggtgt ttgacatccc agcaaagggt 540  
 cccaacattg tactgagcga ggagtggct gggcaccaga tgccaatcac agacattgcc 600  
 accgagcctg ccaggggaca ggattgtgtg gctgacatgg tgacggcaga tgactcaggc 660  
 ttgctgtgtg tctggcggtc agggccagaa ttcacattat tgaccgcat tccaggattt 720  
 ggagttccgt gccctctgt gcagctgtgg caggggatca tagcagcagg ctatgggaac 780  
 ggacaagtgc atctatatga ggccactaca ggaatctac atgtccagat caatgcccat 840  
 gcccgggcca tctgcgccct ggacctggct tctgagggtg gcaagctact ctctgcagg 900  
 gaggacacct ttgtgcata ctggaagctg agcagaaacc cagagagtgg ctacattgag 960  
 gtggaacact gtcatggtga gtgtgtcggc gacaccagc tgtgtggtgc tcgattttgt 1020  
 gattcctcag gcaactcctt tgctgtgact ggctatgacc ttgcggagat ccggagattc 1080  
 agcagtgtgt aagaagagca gccttccttt gtccctgtgg tattcataaa gtaccgcgtc 1140  
 caccctaaa 1148

<210> 25  
 <211> 2419  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc-feature  
 <223> Incyte Clone 3239149

<400> 25  
 cggacgcgtg ggggcctggc accaaagggg cggccccggc ggagagcgga ccagtgggc 60  
 tcggcgatta tggaccgggc cgaggcgggt ctgcaagaga aggcactcaa gtttatgaat 120  
 tctcagaga gagaagactg taataatggc gaaccccta ggaagataat accagagaag 180  
 aattcactta gacagacata caacagctgt gccagactct gcttaacca agaaacagta 240  
 tgttttagca gcaactgctat gaagactgag aattgtgtgg ccaaaacaaa acttgccaat 300  
 ggcaactcca gtatgattgt gcccaagcaa cggaaactct cagcaagcta tgaaaaggaa 360  
 aaggaactgt gtgtcaaata ctttgagcag tggtcagagt cagatcaagt ggaatttgtg 420  
 gaacatctta tatcccaaat gtgtcattac caacatgggc acataaactc gtatcttaaa 480  
 cctatgttgc agagagattt cataactgct ctgccagctc ggggattgga tcatattgct 540  
 gagaacattc tgtcatacct ggatgccaaa tcaactatgt ctgctgaact tgtgtgcaag 600  
 gaatgttacc gagtgcctc tgatggcatg ctgtggaaga agcttatcga gagaatggtc 660  
 aggacagatt ctctgtggag aggcctggca gaacgaagag gatggggaca gtatttattc 720  
 aaaaacaaac ctctgacgg gaattgctcct cccaactctt tttatagagc actttatcct 780  
 aaaattatac aagacattga gacaatagaa tctaattgga gatgtggaag acatagttta 840  
 cagagaattc actgccgaag tgaaacaagc aaaggagttt actgtttaca gtatgatgat 900  
 cagaaaatag taagcggcct tcgagacaac acaatcaaga tctgggataa aaacacattg 960  
 gaatgcaagc gaattctcac aggcataca ggttcagtcc tctgtctcca gtatgatgag 1020  
 agagtgtatc taacaggatc atcggattcc acggtcagag tgtgggatgt aaatacagg 1080  
 gaaatgctaa acacgttgat tcaccattgt gaagcagttc tgcacttgcg tttcaataat 1140

```

ggcatgatgg tgacctgctc caaagatcgt tccattgctg tatgggatat ggcctcccca 1200
actgacatta ccctccggag ggtgctgggc ggacaccgag ctgctgtcaa tgttgtagac 1260
tttgatgaca agtacattgt ttctgcatct ggggatagaa ctataaagggt atggaacaca 1320
agtacttggt aatttgtaag gaccttaaat ggacacaaac gaggcattgc ctgtttgcag 1380
tacagggaca ggctggtagt gagtggctca tctgacaaca ctatcagatt atgggacata 1440
gaatgtgggt catgtttacg agtggttagaa ggccatgagg aattgggtgc ttgtattcga 1500
tttgataaca agaggatagt cagtggggcc tatgatggaa aaattaaagt gtgggatctt 1560
gtggctgctt tggacccccg tgctcctgca gggacactct gtctacggac ccttggtggag 1620
cattccggaa gagtttttcg actacagttt gatgaattcc agattgtcag tagttcacat 1680
gatgacacaa tcctcatctg ggacttccta aatgatccag ctgccaagc tgaaccccc 1740
cgttccctt ctcgaacata cactacatc tccagataaa taaccataca ctgacctcat 1800
acttgcccag gacccattaa agttgcggtt ttaacgtat ctgccaatac caggatgagc 1860
aacaacagta acaatcaaac tactgcccag ttccctgga ctgcccagg agcagggtct 1920
tgagactcct gttgggacac agttggtctg cagtccggcc aggacggctc actcagcaca 1980
actgactgct tcagtgtgc tatcagaaga tgtcttctat cttttgtgaa tgattggaac 2040
ttttaaacct cccctcctct cctccttca cctctgcacc tagttttttc ccattggttc 2100
cagacaaagg tgacttataa atatatattag gtgttttngc ccaggaaatc ctcttgcttt 2160
ggccattaa ggcaggagaa ctaggtttcc cctgtatagg gcctgcgggg ggagaggacc 2220
ccactctagg gggtaggggg gggggtgnca gctttcaagg cccagggggc ccaggtgtct 2280
tccccgggta actgcagggg atgtccagga ccgggggggc tacgagcaag gcccggcccc 2340
ataggtctag gggaggggga cagagtccc ctcgtaatag ggctcggggg agggcaggga 2400
aagggaaaca caggatttg 2419

```

&lt;210&gt; 26

&lt;211&gt; 746

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc-feature

&lt;223&gt; Incyte Clone 3315936

&lt;400&gt; 26

```

atttaatatg actcactata gggaatttgg ccctcgagct agagattcgg gcacgagggg 60
ttgcttagac tgcggcccac gtggaaggct cttagccacc ctgcctggcc cgaggagaaa 120
aacaagcaaa tcctagtgtg gggcctggat ggagcaggaa aaaccagtgt cctgcactct 180
ctagcttcaa acagagtcca gcacagtgtg gcacccaccc aagggttcca tgcagtttgc 240
atcaacactg aagacagcca gatggagttc ctggagattg gtggcagtaa accttttcgg 300
tcctactggg aaatgtacct atccaaggga ttgctgtgta tctttgtggt ggattcagca 360
gatcacagcc gattacctga agccaagaaa taccttcac agctaattgc agcaaacc 420
gtacttcctc tggttgtgtt tgcaaacaaa caggatcttg aagcagccta tcacattaca 480
gatatccatg aagctttggc attatctgaa gtgggaaatg acaggaagat gttcttggtt 540
ggaacctacc tgactaagaa tggctcagag ataccctcca ccatgcaaga tgccaaagac 600
ttgattgcac agctggctgc agatgtgcag tgaccaggac tcagcccact gtgcggctca 660
cgactgagat gtcatcagtg ttgaatggca ggcttgaagc caaaggtttc cacctcaaat 720
aaaaattaag ccatttccta ttaaaa 746

```